New

Summary of findings {#CD011444-sec1-0001}
===================

Summary of findings for the main comparisonMefloquine compared with sulfadoxine‐pyrimethamine for preventing malaria in pregnant women**Mefloquine compared with sulfadoxine‐pyrimethamine for preventing malaria in pregnant womenPatient or population:** HIV‐uninfected pregnant women **Setting:** Benin, Gabon, Mozambique, and Tanzania **Intervention:** mefloquine **Comparison:** sulfadoxine‐pyrimethamine**OutcomesAnticipated absolute effects\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)Comments (compared with sulfadoxine‐pyrimethamine)Risk with sulfadoxine‐pyrimethamineRisk with mefloquine**Clinical malaria episodes during pregnancy‐‐IRR 0.83 (0.65 to 1.05)‐ (2 RCTs)⊕⊕⊕⊝ HIGH^a^Mefloquine results in little or no difference in the incidence of clinical malaria episodes during pregnancyMaternal peripheral parasitaemia at delivery43 per 100028 per 1000\
(20 to 37)RR 0.65\
(0.48 to 0.86)5455\
(2 RCTs)⊕⊕⊕⊝ HIGH^a^Mefloquine results in lower maternal peripheral parasitaemia at deliveryPlacental malaria52 per 100054 per 1000 (30 to 97)RR 1.04 (0.58 to 1.86)4668 (2 RCTs)⊕⊕⊝⊝ LOW^a,b,c^\
Due to imprecision and heterogeneityMefloquine may result in little or no difference in placental parasitaemiaMaternal anaemia at delivery219 per 1000184 per 1000 (166 to 206)RR 0.84 (0.76 to 0.94)5469 (2 RCTs)⊕⊕⊕⊝ MODERATE^a,d^\
Due to imprecisionMefloquine probably results in fewer women anaemic at deliveryLow birth weight117 per 1000111 per 1000 (91 to 137)RR 0.95 (0.78 to 1.17)5641 (2 RCTs)⊕⊕⊕⊝ HIGH^a^Mefloquine results in little or no difference in low birth weightStillbirths and abortions31 per 100037 per 1000 (28 to 49)RR 1.20 (0.91 to 1.58)6219 (2 RCTs)⊕⊕⊕⊝ HIGH^a^Mefloquine results in little or no difference in stillbirths or abortionsAEs: vomiting82 per 1000390 per 1000 (338 to 449)RR 4.76 (4.13 to 5.49)6272 (2 RCTs)⊕⊕⊕⊕ HIGH^a^Mefloquine results in a four‐fold increase in vomitingAEs: dizziness94 per 1000396 per 1000 (316 to 496)RR 4.21 (3.36 to 5.27)6272 (2 RCTs)⊕⊕⊕⊝ HIGH^a,b^Mefloquine results in a four‐fold increase in dizziness\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations:** CI: confidence interval; IRR: incidence rate ratio; RCT: randomized controlled trial; RR: risk ratio.**GRADE Working Group grades of evidence.** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.[^2]

[Table 2](#CD011444-tbl-0002){ref-type="table"}Summary of findings 2Mefloquine plus cotrimoxazole compared with cotrimoxazole for preventing malaria in pregnant women**Mefloquine plus cotrimoxazole compared with cotrimoxazole for preventing malaria in pregnant womenPatient or population:** HIV‐infected pregnant women **Setting:** Benin, Kenya, Mozambique, and Tanzania **Intervention:** mefloquine plus cotrimoxazole **Comparison:** cotrimoxazole**OutcomesAnticipated absolute effects\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)Comments (compared with cotrimoxazole)Risk with cotrimoxazoleRisk with mefloquine plus cotrimoxazole**Clinical malaria episodes during pregnancy‐‐IRR 0.76 (0.33 to 1.76)‐\
(1 RCT)⊕⊕⊕⊕ HIGHMefloquine results in little or no difference in the incidence of clinical malaria episodes during pregnancyMaternal peripheral parasitaemia at delivery (PCR)66 per 100034 per 1000\
(20 to 62)RR 0.52\
(0.30 to 0.93)989\
(2 RCTs)⊕⊕⊕⊝ MODERATE^a^Mefloquine probably results in lower maternal peripheral parasitaemia at deliveryPlacental malaria (PCR)68 per 100019 per 1000 (10 to 39)RR 0.28 (0.14 to 0.57)977 (2 RCTs)⊕⊕⊕⊕ HIGH^a^Mefloquine plus cotrimoxazole results in fewer women with placental malaria at deliveryMaternal anaemia at delivery178 per 1000168 per 1000 (130 to 214)RR 0.94 (0.73 to 1.20)1197 (2 RCTs)⊕⊕⊕⊝ MODERATE^a^Mefloquine plus cotrimoxazole probably results in little or no difference in maternal anaemia cases at deliveryLow birth weight118 per 1000141 per 1000 (105 to 188)RR 1.20 (0.89 to 1.60)1220 (2 RCTs)⊕⊕⊕⊝ MODERATE^a^Mefloquine plus cotrimoxazole probably results in little or no difference in low birth weightSpontaneous abortions and stillbirths50 per 100056 per 1000 (21 to 149)RR 1.12 (0.42 to 2.98)1347 (2 RCTs)⊕⊝⊝⊝ VERY LOW^a,b,c^Mefloquine plus cotrimoxazole may result in little or no difference in spontaneous abortions and stillbirthsAEs: vomiting30 per 1000239 per 1000\
(144 to 396)RR 7.95\
(4.79 to 13.18)1055\
(1 RCT)^d^⊕⊕⊕⊕ HIGHMefloquine plus cotrimoxazole results in an eight‐fold increase in vomitingAEs: dizziness75 per 1000296 per 1000\
(214 to 411)RR 3.94\
(2.85 to 5.46)1055\
(1 RCT)^e^⊕⊕⊕⊕ HIGHMefloquine plus cotrimoxazole results in a four‐fold increase in dizziness\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations:** CI: confidence interval; IRR: incidence rate ratio; RCT: randomized controlled trial; RR: risk ratio.**GRADE Working Group grades of evidence.** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.[^3]

Background {#CD011444-sec1-0002}
==========

Description of the condition {#CD011444-sec2-0001}
----------------------------

Malaria is the most important parasitic disease worldwide and is endemic in parts of Africa, Asia, and South America. Pregnant women are at higher risk of malaria infection than non‐pregnant women in the same age group, and are at higher risk of severe illness ([@CD011444-bbs2-0022]; [@CD011444-bbs2-0027]). Malaria infection during pregnancy, particularly the first or second pregnancy, is also associated with adverse outcomes for both mother (severe anaemia) and infant (low birth weight, neonatal mortality; [@CD011444-bbs2-0017]; [@CD011444-bbs2-0036]; [@CD011444-bbs2-0042]; [@CD011444-bbs2-0051]; [@CD011444-bbs2-0054]; [@CD011444-bbs2-0058]). Symptoms most commonly reported by semi‐immune pregnant women with clinical malaria include headache, arthromyalgias, and fever ([@CD011444-bbs2-0020]). In areas of low transmission, pregnant women with malaria parasitaemia frequently present with symptoms and signs such as fever, malaise, headache, and vomiting. The infection may develop into severe complications such as cerebral malaria and pulmonary oedema if untreated, and may be a cause of maternal mortality ([@CD011444-bbs2-0020]).

To reduce the burden and consequences of malaria in pregnancy, the World Health Organization (WHO) currently recommends that pregnant women who live in moderate to high malaria transmission areas in Africa sleep under an insecticide‐treated net (ITN), as described in [@CD011444-bbs2-0030], and receive intermittent preventive treatment (IPT) with sulfadoxine‐pyrimethamine at each scheduled antenatal care visit (provided that doses are at least one month apart) ([@CD011444-bbs2-0069]). IPT is a form of malaria chemoprevention that was tested and adopted as policy in response to both malaria parasites developing resistance to weekly prophylaxis with chloroquine and low compliance with the weekly regimen ([@CD011444-bbs2-0066]). The long elimination half‐life of sulfadoxine‐pyrimethamine allows intermittent dosing while still providing prophylactic cover for the intervening weeks ([@CD011444-bbs2-0065]). IPT is therefore defined as \"administration of a curative treatment dose of an effective antimalarial drug at predefined intervals during pregnancy\" regardless of the presence or absence of current infection ([@CD011444-bbs2-0065]).

Sulfadoxine‐pyrimethamine remains the drug used for IPT in pregnancy, even though resistance has spread in many parts of southern and eastern Africa ([@CD011444-bbs2-0061]; [@CD011444-bbs2-0067]), which is spurring researchers and policy makers to seek safe and effective alternatives to sulfadoxine‐pyrimethamine ([@CD011444-bbs2-0028]).

Description of the intervention {#CD011444-sec2-0002}
-------------------------------

Mefloquine is a 4‐methanolquinoline that is related to quinine. It was originally developed by the US military for preventing malaria in soldiers and has been widely used for preventing malaria in travellers ([@CD011444-bbs2-0053]). Like sulfadoxine‐pyrimethamine, mefloquine has a long elimination half‐life of two to four weeks; in travellers, weekly dosing consists of 250 mg ([@CD011444-bbs2-0029]), and in pregnant women monthly dosing at treatment doses is feasible ([@CD011444-bbs2-0023]).

Mefloquine was first investigated in the 1990s as prophylactic treatment for pregnant women. An observational study raised concerns that mefloquine may be associated with increased risk of stillbirth ([@CD011444-bbs2-0046]); however other trials did not confirm this finding ([@CD011444-bbs2-0049]; [@CD011444-bbs2-0057]). A systematic review considered the safety of mefloquine in pregnancy and concluded that no evidence indicates that mefloquine use in pregnancy carries increased risk for the foetus ([@CD011444-bbs2-0033]). The drug is known to be associated with a range of mild dose‐related transient side effects, such as vomiting, nausea, and dizziness ([@CD011444-bbs2-0021]; [@CD011444-bbs2-0040]; [@CD011444-bbs2-0055]; [@CD011444-bbs2-0059]). Researchers have described severe neuropsychiatric side effects that occur in about one in 10,000 travellers taking mefloquine as chemoprophylaxis ([@CD011444-bbs2-0050]; [@CD011444-bbs2-0056]). Studies conducted in Beninese pregnant women found that dizziness and vomiting are the most frequent adverse effects related to use of mefloquine as IPT in pregnancy ([@CD011444-bbs2-0023]; [@CD011444-bbs2-0009]).

Data show resistance to mefloquine in multi‐drug resistance areas of Thailand ([@CD011444-bbs2-0024]; [@CD011444-bbs2-0047]), but it remains rare in Africa ([@CD011444-bbs2-0018]; [@CD011444-bbs2-0041]; [@CD011444-bbs2-0048]).

How the intervention might work {#CD011444-sec2-0003}
-------------------------------

Malaria chemoprevention is thought to work through clearance or suppression of asymptomatic malaria infection in the peripheral blood of the mother and the placenta ([@CD011444-bbs2-0065]). This reduction in malaria parasitaemia may, however, be insufficient to justify recommendations for widespread prophylactic prescriptions that do not provide subsequent benefit for clinically important outcomes for mother and baby. These outcomes may include a reduction in episodes of maternal malaria, reduced risk of anaemia, and improved birth weight, as well as more substantive outcomes such as a reduction in severe maternal illness or lower rates of spontaneous pregnancy loss and maternal, neonatal, and infant mortality (see [Figure 1](#CD011444-fig-0001){ref-type="fig"}).Figure 1Indicators and impact of malaria infection in mothers and infants.

Effects of malaria chemoprevention may depend on the local malaria epidemiology and thus the level of acquired immunity against malaria in pregnant women. In stable transmission areas, women of reproductive age may be partially immune to malaria, presenting parasitaemia without clinical disease; however, asymptomatic infections may have detrimental effects, such as anaemia and low birth weight. In contrast, in unstable malaria transmission areas, naturally acquired malaria immunity is usually low among adults and malaria infection may be associated with clinical episodes and severe illness.

Primigravidae women are at higher risk of adverse effects of malaria infection than multigravidae women. This is thought to result from women developing antibodies specific to placental‐type parasites when exposed to *Plasmodium falciparum* during their first pregnancy. These antibodies are then present in subsequent pregnancies ([@CD011444-bbs2-0017]). This is seen in multigravidae women as a more specific and efficient immune response and clearing the infection at an earlier stage than in primigravidae women ([@CD011444-bbs2-0064]).

Another potential effect modifier of the susceptibility to malaria infection is HIV status ([@CD011444-bbs2-0044]). In many malaria‐endemic areas, data show that the prevalence of HIV infection, which has been observed to increase the risk of malaria infection, is high among pregnant women ([@CD011444-bbs2-0032]; [@CD011444-bbs2-0063]). Compared with HIV‐uninfected women, HIV‐infected women are more likely to carry malaria parasites in their blood, to have higher parasite densities, and to develop placental parasitaemia, anaemia, and malaria symptoms ([@CD011444-bbs2-0019]; [@CD011444-bbs2-0062]; [@CD011444-bbs2-0063]). This increased risk of malaria is the same in multigravidae (women in their third pregnancy or higher) and in women in their first or second pregnancy ([@CD011444-bbs2-0060]; [@CD011444-bbs2-0063]). Placental malaria infection may also increase the risk of perinatal mother‐to‐child transmission of HIV ([@CD011444-bbs2-0019]).

Use of ITNs during pregnancy has been shown to have a beneficial impact on pregnancy outcomes (reduced prevalence of low birth weight, miscarriage, and placental parasitaemia) in malaria‐endemic Africa ([@CD011444-bbs2-0031]), and this approach could modify the effect of IPT ([@CD011444-bbs2-0043]).

Why it is important to do this review {#CD011444-sec2-0004}
-------------------------------------

The WHO recommends IPT with sulfadoxine‐pyrimethamine for all pregnant women who live in moderate to high malaria transmission areas in Africa ([@CD011444-bbs2-0066]; [@CD011444-bbs2-0069]). However, studies have shown that resistance to sulfadoxine‐pyrimethamine in some regions of Eastern Africa has been increasing steadily during the past two decades ([@CD011444-bbs2-0038]; [@CD011444-bbs2-0045]). Thus, there is an urgent need for more effective antimalarials to prevent malaria during pregnancy.

This review aims to evaluate the efficacy and safety of mefloquine for preventing malaria in pregnant women. These findings could serve as the basis for future guidelines on preventive agents for malaria in pregnant women.

Objectives {#CD011444-sec1-0003}
==========

To assess the effects of mefloquine for preventing malaria in pregnant women ‐ specifically, to evaluate:

the efficacy, safety, and tolerability of mefloquine for preventing malaria in pregnant women; andthe impact of HIV status, gravidity, and use of insect‐treated nets (ITNs) on the effects of mefloquine.

Methods {#CD011444-sec1-0004}
=======

Criteria for considering studies for this review {#CD011444-sec2-0005}
------------------------------------------------

### Types of studies {#CD011444-sec3-0001}

Randomized controlled trials (RCTs) and quasi‐RCTs.

### Types of participants {#CD011444-sec3-0002}

Pregnant women of any gravidity regardless of HIV status, living in malaria‐endemic areas ([@CD011444-bbs2-0026]).

### Types of interventions {#CD011444-sec3-0003}

#### Interventions {#CD011444-sec4-0001}

Mefloquine given to pregnant women as intermittent preventive treatment or as chemoprophylaxis.

#### Controls {#CD011444-sec4-0002}

Placebo, no intervention, or an alternative drug regimen.

### Types of outcome measures {#CD011444-sec3-0004}

#### Maternal {#CD011444-sec4-0003}

Maternal peripheral parasitaemia during pregnancyMaternal peripheral parasitaemia at deliveryPlacental malaria¹Mean haemoglobin and maternal anaemia (moderate and severe) at deliveryClinical malaria episodes during pregnancy

#### Foetal/infant {#CD011444-sec4-0004}

Cord blood parasitaemiaCord blood haemoglobin and anaemia (as defined in the original studies)Mean birth weightLow birth weight prevalence (\< 2500 g)Prematurity prevalence (\< 37 weeks of gestation)Morbidity in first year of life

#### Adverse events {#CD011444-sec4-0005}

Serious adverse events (SAEs)²Illnesses that were life threatening or required hospitalization during pregnancy (SAEs in pregnancy)Adverse pregnancy outcomes: spontaneous abortion, stillbirth, congenital malformationMaternal mortalityPerinatal, neonatal, infant mortalityMother‐to‐child transmission of HIV frequency (at six weeks of age)Non‐serious adverse eventsFrequency and severity of reported all‐cause and drug‐related adverse events

¹Placental malaria diagnosed by histology, microscopy, or any method used in the included study. [Figure 2](#CD011444-fig-0002){ref-type="fig"} shows the relations between different outcomes.Figure 2Conceptual framework of malaria chemoprevention. Reproduced under the terms of a Creative Commons Licence from [@CD011444-bbs2-0051].

²Review authors acknowledge the limitation of analyzing rare serious adverse events because randomized controlled trials usually are not powered enough to detect them.

Search methods for identification of studies {#CD011444-sec2-0006}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

### Electronic searches {#CD011444-sec3-0005}

We searched the following databases using the search terms and strategy described in [Appendix 1](Appendix 1): the Cochrane Infectious Diseases Group Specialized Register (up to 31 January 2018); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (January 2018); MEDLINE (PubMed; from 1966 to 31 January 2018); Embase (OVID; 1974 to 31 January 2018); and Latin American Caribbean Health Sciences Literature (LILACS) (BIREME; 1982 to 31 January 2018). We also searched the Malaria in Pregnancy (MiP) Library ([www.mip‐consortium.org/resources/index.htm](www.mip‐consortium.org/resources/index.htm)), the WHO International Clinical Trial Registry Platform (ICTRP; [www.who.int/ictrp/search/en](www.who.int/ictrp/search/en)), ClinicalTrials.gov, and the International Standard Randomized Controlled Trial Number (ISRCTN) registry ([www.isrctn.com/](www.isrctn.com/)), using 'mefloquine\', 'malaria\', and 'pregnan\*\' as search terms.

### Searching other resources {#CD011444-sec3-0006}

We contacted researchers working in the field to ask for unpublished data, confidential reports, and raw data from published trials. We also checked the citations of all trials identified by the methods described.

Data collection and analysis {#CD011444-sec2-0007}
----------------------------

### Selection of studies {#CD011444-sec3-0007}

Two review authors independently screened all trials identified by the search strategy by title or abstract, or both ([Appendix 1](#CD011444-sec2-0016){ref-type="app"}). We coded studies as 'retrieve\' or 'do not retrieve\'. We retrieved the full‐text copies of trials deemed potentially relevant. Two review authors then independently assessed study eligibility using a form based on the review inclusion criteria. We resolved disagreements through discussion or by consultation with a third review author. Any review author who participated in trials that potentially met the review inclusion criteria did not participate in the procedure to select studies for inclusion. We listed all studies excluded after full‐text assessment and reasons for their exclusion in a '[Characteristics of excluded studies](#CD011444-sec2-0020){ref-type="sec"}\' table. We illustrated the study selection process in a PRISMA diagram.

### Data extraction and management {#CD011444-sec3-0008}

Three review authors (RG, CPD, and MP) used a data extraction form to independently extract data on trial characteristics, including trial site, year, local malaria transmission estimates, antimalarial resistance pattern of mefloquine and the comparator drug (when possible), trial methods, participants, interventions, doses, and outcomes.

We extracted the number of participants randomized and the number of participants analyzed in experimental and control groups for each outcome. For dichotomous outcomes, we extracted the number of participants experiencing the event and the number assessed in each treatment group. For continuous outcomes, we extracted the arithmetic means, standard deviations for each treatment group (when provided), and the number of participants assessed in each group. We also extracted medians and ranges when provided. For outcomes reported as incidences, we extracted the number of participants experiencing the event (cases) and the person‐years at risk.

Any review author who participated in any of the trials included in the review did not participate in data extraction nor 'Risk of bias\' assessment of their own articles.

### Assessment of risk of bias in included studies {#CD011444-sec3-0009}

Two review authors independently assessed the risk of bias for each included trial using the Cochrane 'Risk of bias\' assessment tool ([@CD011444-bbs2-0037]). This approach assesses the risk of bias across seven domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias ([@CD011444-bbs2-0037]). For each domain, we assigned a judgment of low, high, or unclear risk of bias. We judged the risk of bias for blinding on the presence of blinding and whether lack of blinding could potentially influence the results.

### Measures of treatment effect {#CD011444-sec3-0010}

We presented dichotomous outcomes using risk ratios (RRs), count outcomes as incidence rate ratios (IRRs), and continuous outcomes as mean differences (MDs). We presented all measures of effect with 95% confidence intervals (CIs).

### Unit of analysis issues {#CD011444-sec3-0011}

When conducting a meta‐analysis, we ensured that participants and cases in the placebo group were not counted more than once.

### Dealing with missing data {#CD011444-sec3-0012}

We aimed to conduct the analysis according to the intention‐to‐treat principle. However, when there was loss to follow‐up, we used a complete‐case analysis such that participants for whom no outcome was reported were excluded from the analysis. This analysis assumes that participants for whom an outcome is available are representative of the original randomized patients. We aimed to conduct a sensitivity analysis to evaluate the robustness of this method, but this was not possible, as described below. If data from trial reports were insufficient, unclear, or missing, we contacted the study authors for additional information.

### Assessment of heterogeneity {#CD011444-sec3-0013}

We calculated the I^2^ statistic using values of 30% to 59%, 60% to 89%, and 90% to 100% to denote moderate, substantial, and considerable levels of heterogeneity, respectively.

### Assessment of reporting biases {#CD011444-sec3-0014}

We aimed to assess the risk of publication bias by constructing funnel plots and looking for asymmetry, but the small number of trials included in each comparison of the meta‐analysis made this assessment impossible.

### Data synthesis {#CD011444-sec3-0015}

We performed data analysis using Review Manager 5 (RevMan 5) ([@CD011444-bbs2-0052]). We intended to perform subgroup analysis by gravidity and HIV status when possible. HIV status subgroup analysis was not possible in any case owing to different study designs for different HIV status populations. In the absence of heterogeneity, we used a fixed‐effect model for the meta‐analysis; when we detected moderate or considerable heterogeneity, we used a random‐effects model. Additionally, we assessed the certainty of evidence using the GRADE approach ([@CD011444-bbs2-0035]) for the following main outcomes of analysis: maternal peripheral parasitaemia at delivery, clinical malaria episodes during pregnancy, placental malaria, maternal anaemia at delivery, low birth weight, spontaneous abortion and stillbirth, dizziness, and vomiting.

### Subgroup analysis and investigation of heterogeneity {#CD011444-sec3-0016}

We aimed to investigate heterogeneity by conducting prespecified subgroup analysis to evaluate the contributions of differences in trial characteristics such as risk of bias, geographical region, malaria transmission pattern, antimalarial resistance, drug regimen, use of ITNs, gravidity (primigravidae versus multigravidae), HIV status (uninfected, infected, unknown), and trial methods. Only the gravidity subgroup analysis was possible for one outcome of the main comparison. The other subgroup analyses were not possible because of the small number of trials included in each comparison.

### Sensitivity analysis {#CD011444-sec3-0017}

We planned to conduct a sensitivity analysis to restore the integrity of the randomization process and to test the robustness of our results; however, the small number of trials included in each comparison -- two at most -- made this impossible. Additionally, missing outcome data were balanced in numbers across intervention groups, and reasons for missing data were similar across groups.

Results {#CD011444-sec1-0005}
=======

Description of studies {#CD011444-sec2-0008}
----------------------

### Results of the search {#CD011444-sec3-0018}

The literature search, conducted up to 31 January 2018, identified 254 references, of which two were duplicate trial reports. Of the 252 remaining articles, we excluded 231 articles and one ongoing trial after title/abstract screening. We assessed 20 full‐text articles for eligibility, of which we excluded 14 articles. Six trials (in six publications) met the inclusion criteria of the review ([Figure 3](#CD011444-fig-0003){ref-type="fig"}).Figure 3Study flow diagram.

### Included studies {#CD011444-sec3-0019}

Six chemoprevention trials that included 8192 pregnant women met our inclusion criteria (see the [Characteristics of included studies](#CD011444-sec2-0019){ref-type="sec"} section). These trials were conducted between 1987 and 2013 in Thailand (one trial), Benin (three trials), Gabon (one trial), Kenya (one trial), Mozambique (two trials), and Tanzania (two trials).

The included trials recruited women of all gravidities of all ages (four trials) or over 18 years of age (two trials). Gestational age at recruitment was greater than 20 weeks (one trial), between 16 and 28 weeks (three trials), or ≤ 28 weeks (two trials).

Two trials evaluated mefloquine against sulfadoxine‐pyrimethamine as IPTp in HIV‐uninfected pregnant women. Three trials evaluated mefloquine IPTp alone (or in combination with daily cotrimoxazole) against cotrimoxazole in HIV‐infected pregnant women. Finally, one trial in Thailand compared weekly mefloquine prophylaxis against placebo in women of unknown HIV status. All included trials reported that drug administration was supervised.

All included trials recruited women in all gravidity groups; five reported aggregate results and one disaggregated by gravidity for the primary outcome. In five trials, all women in both intervention and control groups received a long‐lasting ITN at recruitment and iron, and investigators routinely administered folic acid.

### Excluded studies {#CD011444-sec3-0020}

We excluded one trial for the reasons given in the '[Characteristics of excluded studies](#CD011444-sec2-0020){ref-type="sec"}\' table.

Risk of bias in included studies {#CD011444-sec2-0009}
--------------------------------

See [Figure 4](#CD011444-fig-0004){ref-type="fig"} and [Figure 5](#CD011444-fig-0005){ref-type="fig"} for a summary of the 'Risk of bias\' assessments. We have presented further details in the '[Characteristics of included studies](#CD011444-sec2-0019){ref-type="sec"}\' table.Figure 4'Risk of bias\' summary: review authors\' judgements about each risk of bias item for each included study.Figure 5'Risk of bias\' graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.

### Allocation {#CD011444-sec3-0021}

#### Random sequence generation (selection bias) {#CD011444-sec4-0006}

Two trials adequately described methods of sequence generation ([@CD011444-bbs2-0004]; [@CD011444-bbs2-0005]), three described a non‐random component in the sequence generation process ([@CD011444-bbs2-0001]; [@CD011444-bbs2-0002]; [@CD011444-bbs2-0003]), and in the remaining trial, the risk was unclear ([@CD011444-bbs2-0006]).

#### Allocation concealment (selection bias) {#CD011444-sec4-0007}

Four trials described adequate methods of allocation concealment ([@CD011444-bbs2-0002]; [@CD011444-bbs2-0003]; [@CD011444-bbs2-0004]; [@CD011444-bbs2-0005]), one trial reported no concealment of allocation ([@CD011444-bbs2-0001]), and in the remaining trial, the risk was unclear ([@CD011444-bbs2-0006]).

### Blinding {#CD011444-sec3-0022}

#### Blinding of participants and personnel (performance bias) {#CD011444-sec4-0008}

Four trials were open ([@CD011444-bbs2-0001]; [@CD011444-bbs2-0002]; [@CD011444-bbs2-0003]; [@CD011444-bbs2-0004]), and we assessed these as having high risk of performance risk. Two trials were double‐blind and placebo‐controlled ([@CD011444-bbs2-0005]; [@CD011444-bbs2-0006]), and we assessed these as having low risk of performance bias.

#### Blinding of efficacy outcome assessment (detection bias) {#CD011444-sec4-0009}

For five trials, we judged the efficacy outcome as not influenced by blinding or lack of blinding. In the remaining trial, the risk of detection bias for efficacy outcomes was unclear ([@CD011444-bbs2-0006]).

#### Blinding of safety outcome assessment (detection bias) {#CD011444-sec4-0010}

For the four open trials, we judged the risk of detection bias as high for assessment of safety outcomes ([@CD011444-bbs2-0001]; [@CD011444-bbs2-0002]; [@CD011444-bbs2-0003]; [@CD011444-bbs2-0004]). In one trial, the risk of detection bias was unclear ([@CD011444-bbs2-0006]). For the remaining trial, which was double‐blinded, we judged the risk of detection bias as low ([@CD011444-bbs2-0005]).

### Incomplete outcome data {#CD011444-sec3-0023}

In all included trials, missing outcome data were balanced in numbers across groups, and we judged the risk of attrition bias to be low.

### Selective reporting {#CD011444-sec3-0024}

We considered the risk of reporting bias as low in five trials and unclear in one ([@CD011444-bbs2-0006]).

### Other potential sources of bias {#CD011444-sec3-0025}

All included trials appeared to be free of other sources of bias, and we judged this risk as low.

Effects of interventions {#CD011444-sec2-0010}
------------------------

See: [Table 1](#CD011444-tbl-0001){ref-type="table"}; [Table 2](#CD011444-tbl-0002){ref-type="table"}

### Comparison 1: Mefloquine versus sulfadoxine‐pyrimethamine (HIV‐uninfected pregnant women) {#CD011444-sec3-0026}

See [Table 1](#CD011444-tbl-0001){ref-type="table"}.

#### Maternal outcomes {#CD011444-sec4-0011}

We included in this comparison two trials that evaluated two doses of IPTp ([@CD011444-bbs2-0001]; [@CD011444-bbs2-0004]). Data show a decrease in the number of clinical malaria episodes during pregnancy among mefloquine recipients, but this does not clearly constitute an effect of mefloquine because the 95% CIs do not exclude the possibility of no different effects (IRR 0.83, 95% CI 0.65 to 1.05; 2 studies; *high‐certainty evidence*; [Analysis 1.1](#CD011444-fig-00101){ref-type="fig"}). Overall, IPTp‐mefloquine was associated with a 35% reduction in the risk of maternal peripheral parasitaemia at delivery (RR 0.65, 95% CI 0.48 to 0.86; 5455 participants, 2 studies; I^2^ statistic = 16%; *moderate‐certainty evidence*; [Analysis 1.2](#CD011444-fig-00102){ref-type="fig"}), but the absolute difference between treatments was small. We found no significant evidence of an effect of mefloquine or sulfadoxine‐pyrimethamine on placental malaria infections (RR 1.04, 95% CI 0.58 to 1.86; 4668 participants, 2 studies; I^2^ statistic = 63%; *low‐certainty evidence*; [Analysis 1.3](#CD011444-fig-00103){ref-type="fig"}). The mefloquine group showed a slight increase in the mean haemoglobin level at delivery (MD 0.10, 95% CI 0.01 to 0.19; 5588 participants, 2 studies; I^2^ statistic = 0%; [Analysis 1.4](#CD011444-fig-00104){ref-type="fig"}) and a decrease in maternal anaemia cases at delivery (RR 0.84, 95% CI 0.76 to 0.94; 5469 participants, 2 studies; I^2^ statistic = 0%; *moderate‐certainty evidence*; [Analysis 1.5](#CD011444-fig-00105){ref-type="fig"}), but the data show no significant differences in severe maternal anaemia at delivery between groups (RR 0.93, 95% CI 0.58 to 1.48; 5469 participants, 2 studies; I^2^ statistic = 41%; [Analysis 1.6](#CD011444-fig-00106){ref-type="fig"}). The original definitions of maternal moderate anaemia and severe maternal anaemia were different in the two trials included in the analysis ([@CD011444-bbs2-0004] defined anaemia as haemoglobin \< 11 g/dL and severe anaemia as haemoglobin \< 7 g/dL), but we homogenized data for the analysis as \< 9.5 g/dL and \< 8 g/dL (as defined in [@CD011444-bbs2-0001]), respectively.

#### Foetal/infant outcomes {#CD011444-sec4-0012}

No effect was evident for the outcomes of cord blood parasitaemia (RR 0.44, 95% CI 0.13 to 1.46; 5309 participants, 2 studies; I^2^ statistic = 33%; [Analysis 1.7](#CD011444-fig-00107){ref-type="fig"}) and cord blood anaemia (RR 1.04, 95% CI 0.87 to 1.23; 4006 participants, 1 study; [Analysis 1.8](#CD011444-fig-00108){ref-type="fig"}).

Regarding newborn outcomes, mean birth weight did not show significant differences between groups (MD 2.52, 95% CI ‐25.66 to 30.69; 5241 participants, 2 studies; I^2^ statistic = 0%; [Analysis 1.9](#CD011444-fig-00109){ref-type="fig"}). Low birth weight (RR 0.95, 95% CI 0.78 to 1.17; 5641 participants, 2 studies; I^2^ statistic = 33%; *moderate‐certainty evidence*; [Analysis 1.10](#CD011444-fig-00110){ref-type="fig"}) and prematurity prevalence (RR 1.03, 95% CI 0.76 to 1.40; 4640 participants, 2 studies; I^2^ statistic = 0%; [Analysis 1.12](#CD011444-fig-00112){ref-type="fig"}) also showed no differences between groups. Subgroup analysis of low birth weight by gravidity yielded results that did not vary (primigravidae: RR 1.02, 95% CI 0.80 to 1.30; 1576 participants, 2 studies; I^2^ statistic = 3%; [Analysis 1.11](#CD011444-fig-00111){ref-type="fig"}; multigravidae: RR 0.94, 95% CI 0.78 to 1.14; 4065 participants, 2 studies; I^2^ statistic = 0%; [Analysis 1.11](#CD011444-fig-00111){ref-type="fig"}).

Only one trial reported data on infant morbidity, and results followed the same trend; the IRR was near 1, and the CIs did not discard the possibility of no difference between mefloquine and sulfadoxine‐pyrimethamine. Chosen proxies for infant morbidity were malaria in the first year of life (IRR 0.97, 95% CI 0.82 to 1.15; 1 study; [Analysis 1.13](#CD011444-fig-00113){ref-type="fig"}) and hospital admissions in the first year of life (IRR 0.93, 95% CI 0.75 to 1.17; 1 study; [Analysis 1.14](#CD011444-fig-00114){ref-type="fig"}).

#### Safety outcomes {#CD011444-sec4-0013}

No difference was evident between mefloquine and sulfadoxine‐pyrimethamine in overall serious adverse events reporting (RR 0.98, 95% CI 0.81 to 1.20; 4674 participants, 1 study; [Analysis 1.15](#CD011444-fig-00115){ref-type="fig"}). Definitions of stillbirth and abortion were different for the two trials included in this comparison; therefore we aggregated both outcomes into a single outcome (RR 1.20, 95% CI 0.91 to 1.58; 6219 participants, 2 studies; I^2^ statistic = 0%; *moderate‐certainty evidence*; [Analysis 1.16](#CD011444-fig-00116){ref-type="fig"}). Congenital malformation cases were also similar in both intervention groups (RR 1.10, 95% CI 0.51 to 2.37; 5931 participants, 2 studies; I^2^ statistic = 33%; [Analysis 1.17](#CD011444-fig-00117){ref-type="fig"}).

Regarding maternal mortality, one of the trials reported maternal deaths only in the mefloquine group, and the other trial showed a similar proportion of maternal deaths in both IPTp groups; the CI of the meta‐analysis was wide, and heterogeneity was moderate (RR 2.41, 95% CI 0.27 to 21.23; 6219 participants, 2 studies; I^2^ statistic = 54%; [Analysis 1.18](#CD011444-fig-00118){ref-type="fig"}). Only one of the trials reported neonatal and infant mortality ([@CD011444-bbs2-0004]), but we obtained neonatal mortality rates for the other trial by contacting the study authors ([@CD011444-bbs2-0001]). Neither of the two outcomes showed a significant effect of mefloquine or sulfadoxine‐pyrimethamine (neonatal deaths: RR 0.98, 95% CI 0.67 to 1.43; 6134 participants, 2 studies; I^2^ statistic = 0%; [Analysis 1.19](#CD011444-fig-00119){ref-type="fig"}; incidence of infant deaths: IRR 1.00, 95% CI 0.66 to 1.52; 1 study; [Analysis 1.20](#CD011444-fig-00120){ref-type="fig"}).

Overall, IPTp‐mefloquine increased the risk of adverse events; results of individual trials and of meta‐analyses were significant for vomiting (RR 4.76, 95% CI 4.13 to 5.49; 6272 participants, 2 studies; I^2^ statistic = 0%; *high‐certainty evidence*; [Analysis 1.21](#CD011444-fig-00121){ref-type="fig"}), fatigue/weakness (RR 4.62, 95% CI 1.80 to 11.85; 6272 participants, 2 studies; I^2^ statistic = 91%; *high‐certainty evidence*; [Analysis 1.22](#CD011444-fig-00122){ref-type="fig"}), and dizziness (RR 4.21, 95% CI 3.36 to 5.27; 6272 participants, 2 studies; I^2^ statistic = 66%; *moderate‐certainty evidence*; [Analysis 1.23](#CD011444-fig-00123){ref-type="fig"}), with the exception of headache (RR 0.70, 95% CI 0.25 to 1.94; 6272 participants, 2 studies; I^2^ statistic = 85%; [Analysis 1.24](#CD011444-fig-00124){ref-type="fig"}).

### Comparison 2: Mefloquine plus cotrimoxazole versus cotrimoxazole (HIV‐infected pregnant women) {#CD011444-sec3-0027}

See [Table 2](#CD011444-tbl-0002){ref-type="table"}.

#### Maternal outcomes {#CD011444-sec4-0014}

This comparison included two trials evaluating three IPTp doses of mefloquine ([@CD011444-bbs2-0002]; [@CD011444-bbs2-0005]). Only one of the trials reported clinical malaria episodes during pregnancy, noting no significant differences in malaria episodes between groups (IRR 0.76, 95% CI 0.33 to 1.76; 1 study; *high certainty evidence*; [Analysis 2.1](#CD011444-fig-00201){ref-type="fig"}). IPTp‐mefloquine plus cotrimoxazole prophylaxis was associated with a 48% reduction in the risk of maternal peripheral parasitaemia at delivery measured by polymerase chain reaction (PCR) (RR 0.52, 95% CI 0.30 to 0.93; 989 participants, 2 studies; I^2^ statistic = 0%; *moderate‐certainty evidence*; [Analysis 2.2](#CD011444-fig-00202){ref-type="fig"}), a 49% reduction in the risk of placental malaria measured by blood smear (RR 0.51, 95% CI 0.29 to 0.89; 1144 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.3](#CD011444-fig-00203){ref-type="fig"}), and a 72% reduction in the risk of placental malaria measured by PCR (RR 0.28, 95% CI 0.14 to 0.57; 977 participants, 2 studies; I^2^ statistic = 0%; *high‐certainty evidence*; [Analysis 2.4](#CD011444-fig-00204){ref-type="fig"}). The other maternal‐related outcomes at delivery included in this comparison did not show evidence that they were effects of mefloquine owing to the wideness of the CIs (mean haemoglobin: MD 0.07, 95% CI ‐0.32 to 0.46; 1167 participants, 2 studies; I^2^ statistic = 62%; [Analysis 2.5](#CD011444-fig-00205){ref-type="fig"}; maternal anaemia: RR 0.94, 95% CI 0.73 to 1.20; 1197 participants, 2 studies; I^2^ statistic = 12%; *moderate‐certainty evidence*; [Analysis 2.6](#CD011444-fig-00206){ref-type="fig"}; severe maternal anaemia: RR 0.93, 95% CI 0.41 to 2.08; 1167 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.7](#CD011444-fig-00207){ref-type="fig"}). The original definitions of maternal anaemia were different in the two trials included in the analysis ([@CD011444-bbs2-0005] defined anaemia as haemoglobin \< 11 g/dL), but we homogenized definitions for the analysis as \< 9.5 g/dL (as defined in [@CD011444-bbs2-0002]). The two trials defined severe maternal anaemia as haemoglobin \< 7 g/dL.

#### Foetal/infant outcomes {#CD011444-sec4-0015}

Meta‐analyses of foetal and neonatal outcomes were underpowered to detect significant effects of mefloquine on cord blood parasitaemia (RR 0.33, 95% CI 0.03 to 3.13; 1166 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.8](#CD011444-fig-00208){ref-type="fig"}), mean birth weight (MD ‐25.75, 95% CI ‐86.99 to 35.49; 1220 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.9](#CD011444-fig-00209){ref-type="fig"}), low birth weight rates (RR 1.20, 95% CI 0.89 to 1.60; 1220 participants, 2 studies; I^2^ statistic = 0%; *moderate‐certainty evidence*; [Analysis 2.10](#CD011444-fig-00210){ref-type="fig"}), and prematurity rates (RR 1.07, 95% CI 0.58 to 1.72; 824 participants, 2 studies; I^2^ statistic = 32%; [Analysis 2.11](#CD011444-fig-00211){ref-type="fig"}). These CIs did not exclude the possibility of no different effects between groups.

#### Safety outcomes {#CD011444-sec4-0016}

Overall, serious adverse events during pregnancy were significantly less frequent in the group of IPTp‐mefloquine plus cotrimoxazole prophylaxis than in the cotrimoxazole alone group (RR 0.69, 95% CI 0.50 to 0.95; 1347 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.12](#CD011444-fig-00212){ref-type="fig"}). However, analysis of individual adverse events did not show differences between groups, for example, spontaneous abortions and stillbirths (RR 1.12, 95% CI 0.42 to 2.98; 1347 participants, 2 studies; I^2^ statistic = 69%; *very low‐certainty evidence*; [Analysis 2.13](#CD011444-fig-00213){ref-type="fig"}) and congenital malformations (RR 0.61, 95% CI 0.22 to 1.67; 1312 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.14](#CD011444-fig-00214){ref-type="fig"}). Definitions of spontaneous abortion and stillbirth were different in the two included trials (that is, difference in the gestational age cutoff for classifying miscarriage or stillbirth); therefore, we combined both indicators and analyzed them as one. Only one trial included information on maternal deaths ([@CD011444-bbs2-0005]), and we obtained this information by contacting the authors in the other trial ([@CD011444-bbs2-0002]). Analyses of maternal deaths revealed no significant differences between groups (RR 0.51, 95% CI 0.13 to 2.01; 1347 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.15](#CD011444-fig-00215){ref-type="fig"}). Also, we found that neonatal mortality rates were not significantly different among groups, as revealed by the CI (RR 1.32, 95% CI 0.65 to 2.69; 1239 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.16](#CD011444-fig-00216){ref-type="fig"}). It is important to note that mefloquine plus cotrimoxazole recipients were at 1.92 times greater risk of mother‐to‐child transmission of HIV than the group that took only cotrimoxazole (RR 1.92, 95% CI 1.13 to 3.25; 1019 participants, 2 studies; I^2^ statistic = 0%; [Analysis 2.17](#CD011444-fig-00217){ref-type="fig"}).

Vomiting, fatigue/weakness, and dizziness displayed substantial and considerable levels of heterogeneity in the meta‐analysis. Individual trials showed significant increases in three drug‐related adverse events in the groups given IPTp‐mefloquine plus cotrimoxazole prophylaxis, but random‐effects analyses show a significant effect of IPTp‐mefloquine only in the case of vomiting (RR 20.88, 95% CI 1.40 to 311.66; 1347 participants, 2 studies; I^2^ statistic = 74%; [Analysis 2.18](#CD011444-fig-00218){ref-type="fig"}), while fatigue (RR 2.95, 95% CI 0.26 to 32.93; 1347 participants, 2 studies; I^2^ statistic = 91%; [Analysis 2.19](#CD011444-fig-00219){ref-type="fig"}) and dizziness (RR 16.34, 95% CI 0.39 to 684.99; 1347 participants, 2 studies; I^2^ statistic = 86%; [Analysis 2.20](#CD011444-fig-00220){ref-type="fig"}) show no significant evidence. In the three cases, CIs are considerably wide. Headache cases were not significantly different across groups (RR 0.76, 95% CI 0.28 to 2.10; 1347 participants, 2 studies; I^2^ statistic = 30%; [Analysis 2.21](#CD011444-fig-00221){ref-type="fig"}).

### Comparison 3: Mefloquine versus cotrimoxazole (HIV‐infected pregnant women) {#CD011444-sec3-0028}

#### Maternal outcomes {#CD011444-sec4-0017}

Only one trial conducted in Benin provided data on this comparison of three IPTp‐mefloquine doses versus cotrimoxazole prophylaxis ([@CD011444-bbs2-0003]). The few observations reported in the trial made the analyses, in general, underpowered to detect differences between groups. Efficacy outcomes directly related to malaria yielded RR indicating beneficial effects of IPTp‐mefloquine in reducing infection, but CIs did not exclude the possibility of no difference between groups (maternal peripheral parasitaemia during pregnancy measured by PCR: RR 0.21, 95% CI 0.03 to 1.72; 98 participants, 1 study; [Analysis 3.1](#CD011444-fig-00301){ref-type="fig"}; placental malaria measured by PCR: RR 0.73, 95% CI 0.13 to 4.15; 94 participants, 1 study; [Analysis 3.2](#CD011444-fig-00302){ref-type="fig"}; placental malaria measured by blood smear: RR 0.35, 95% CI 0.01 to 8.30; 108 participants, 1 study; [Analysis 3.3](#CD011444-fig-00303){ref-type="fig"}). Data show no differences across groups for mean haemoglobin (MD ‐0.10, 95% CI ‐0.67 to 0.47; 100 participants, 1 study; [Analysis 3.4](#CD011444-fig-00304){ref-type="fig"}) or maternal anaemia at delivery (RR 0.90, 95% CI 0.26 to 3.16; 100 participants, 1 study; [Analysis 3.5](#CD011444-fig-00305){ref-type="fig"}).

#### Foetal/infant outcomes {#CD011444-sec4-0018}

All newborn outcomes included in the trial displayed wide CIs, providing no evidence of differences between groups (mean birth weight: MD ‐102.00, 95% CI ‐255.52 to 51.52; 120 participants, 1 study; [Analysis 3.6](#CD011444-fig-00306){ref-type="fig"}; low birth weight rate: RR 1.52, 95% CI 0.56 to 4.13; 120 participants, 1 study; [Analysis 3.7](#CD011444-fig-00307){ref-type="fig"}; prematurity rate: RR 1.08, 95% CI 0.33 to 3.56; 125 participants, 1 study; [Analysis 3.8](#CD011444-fig-00308){ref-type="fig"}).

#### Safety outcomes {#CD011444-sec4-0019}

Serious adverse events reported in the trial were balanced across groups and were infrequent. The CIs reveal the possibility of no different effects between interventions in overall serious adverse events (RR 1.06, 95% CI 0.28 to 4.07; 140 participants, 1 study; [Analysis 3.9](#CD011444-fig-00309){ref-type="fig"}), stillbirths (RR 4.30, 95% CI 0.49 to 37.49; 139 participants, 1 study; [Analysis 3.10](#CD011444-fig-00310){ref-type="fig"}), spontaneous abortions (RR 1.07, 95% CI 0.07 to 16.84; 139 participants, 1 study; [Analysis 3.11](#CD011444-fig-00311){ref-type="fig"}), and congenital malformations (RR 1.07, 95% CI 0.16 to 7.41; 139 participants, 1 study; [Analysis 3.12](#CD011444-fig-00312){ref-type="fig"}). No maternal deaths occurred during the trial (139 participants, 1 study; [Analysis 3.13](#CD011444-fig-00313){ref-type="fig"}), and only one neonate in each intervention group died (RR 1.05, 95% CI 0.07 to 16.39; 129 participants, 1 study; [Analysis 3.14](#CD011444-fig-00314){ref-type="fig"}). The trial did not record infant mortality and regarded infant deaths after seven days of birth until six weeks of age as a proxy; small numbers of observations and infant deaths made demonstration of differences between groups impossible (RR 2.10, 95% CI 0.19 to 22.54; 129 participants, 1 study; [Analysis 3.15](#CD011444-fig-00315){ref-type="fig"}).

Drug‐related adverse events were significantly more frequent in the mefloquine group. Despite wide CIs, results show an effect of mefloquine in increasing the frequency of vomiting (RR 13.43, 95% CI 3.31 to 54.54; 139 participants, 1 study; [Analysis 3.16](#CD011444-fig-00316){ref-type="fig"}), fatigue/weakness (RR 6.99, 95% CI 1.64 to 29.81; 139 participants, 1 study; [Analysis 3.17](#CD011444-fig-00317){ref-type="fig"}), and dizziness (RR 52.60, 95% CI 3.26 to 848.24; 139 participants, 1 study; [Analysis 3.18](#CD011444-fig-00318){ref-type="fig"}). Data show no differences between groups in drug‐related headache (RR 0.21, 95% CI 0.01 to 4.39; 139 participants, 1 study; [Analysis 3.19](#CD011444-fig-00319){ref-type="fig"}).

### Comparison 4: Mefloquine versus placebo (pregnant women of unknown HIV status) {#CD011444-sec3-0029}

#### Maternal and foetal/infant outcomes {#CD011444-sec4-0020}

Only one trial provided data on this comparison, which comprised two phases of mefloquine prophylaxis with different doses of the drug ([@CD011444-bbs2-0006]); the results belong to the pooled samples of both trial phases. This trial did not report clinical malaria episodes during pregnancy, maternal anaemia at delivery, cord blood parasitaemia and anaemia, serious adverse events, neonatal mortality, and adverse events, or data reporting was incomplete.

The only observed significant effect that could be attributed to mefloquine was the decrease in maternal peripheral parasitaemia at delivery (RR 0.13, 95% CI 0.05 to 0.33; 339 participants, 1 study; [Analysis 4.1](#CD011444-fig-00401){ref-type="fig"}). The other efficacy outcomes evaluated in this trial ‐ both maternal and newborn‐related outcomes ‐ showed wide CIs and did not demonstrate different effects between placebo and mefloquine prophylaxis (placental malaria: RR 0.14, 95% CI 0.01 to 2.68; 220 participants, 1 study; [Analysis 4.2](#CD011444-fig-00402){ref-type="fig"}; mean birth weight: MD ‐80.00, 95% CI ‐184.65 to 24.65; 290 participants, 1 study; [Analysis 4.3](#CD011444-fig-00403){ref-type="fig"}; low birth weight: RR 1.39, 95% CI 0.78 to 2.48; 290 participants, 1 study; [Analysis 4.4](#CD011444-fig-00404){ref-type="fig"}; prematurity: RR 0.48, 95% CI 0.15 to 1.53; 199 participants, 1 study; [Analysis 4.5](#CD011444-fig-00405){ref-type="fig"}).

#### Safety outcomes {#CD011444-sec4-0021}

This trial reported only serious adverse events, and adverse events data were not complete in the published article. Stillbirths were more prevalent in the group given mefloquine prophylaxis, but the small number of observed events made the analysis unpowered to detect differences between groups (RR 2.63, 95% CI 0.86 to 8.08; 311 participants, 1 study; [Analysis 4.6](#CD011444-fig-00406){ref-type="fig"}). Investigators reported only three spontaneous abortions and five congenital malformations, thus the CIs of analyses were very wide to detect differences in effects (spontaneous abortion: RR 0.48, 95% CI 0.04 to 5.22; 311 participants, 1 study; [Analysis 4.7](#CD011444-fig-00407){ref-type="fig"}; congenital malformation: RR 3.82, 95% CI 0.43 to 33.83; 311 participants, 1 study; [Analysis 4.8](#CD011444-fig-00408){ref-type="fig"}). During the trial, only one maternal death occurred in the mefloquine group, but the power of the analysis was too low to attribute the effects to an intervention (RR 2.95, 95% CI 0.12 to 71.85; 339 participants, 1 study; [Analysis 4.9](#CD011444-fig-00409){ref-type="fig"}). Infant deaths were equally frequent in both trial groups (RR 1.04, 95% CI 0.63 to 1.74; 288 participants, 1 study; [Analysis 4.10](#CD011444-fig-00410){ref-type="fig"}).

Discussion {#CD011444-sec1-0006}
==========

Summary of main results {#CD011444-sec2-0011}
-----------------------

We included in this Cochrane Review six trials, enrolling 8192 pregnant women.

For HIV‐uninfected women, two doses of intermittent preventive mefloquine treatment in pregnancy (IPTp‐mefloquine) reduced the risk of maternal peripheral parasitaemia at delivery by 35% (*moderate‐certainty evidence*) and the risk of anaemia by 16% (*moderate‐certainty evidence*) compared with two doses of intermittent preventive sulfadoxine‐pyrimethamine treatment in pregnancy (IPTp‐sulfadoxine‐pyrimethamine). Investigators have reported no significant evidence of an effect of mefloquine on placental malaria, cord blood parasitaemia and anaemia, mean birth weight, prevalence of low birth weight, prematurity, stillbirths and abortions, and congenital malformations. Overall, IPTp‐mefloquine increases by approximately four‐fold the risk of drug‐related adverse events including vomiting, fatigue/weakness, and dizziness (*moderate‐certainty evidence*), when compared with sulfadoxine‐pyrimethamine.

For HIV‐infected women, three doses of IPTp‐mefloquine plus cotrimoxazole prophylaxis compared with cotrimoxazole alone reduced the risk of maternal peripheral parasitaemia at delivery (measured by polymerase chain reaction (PCR)) by 48% (*moderate‐certainty evidence*) and the risk of placental malaria (measured by PCR) by 72% (*high‐certainty evidence*). Meta‐analyses were underpowered to detect differences between effects of mefloquine plus cotrimoxazole and cotrimoxazole on other maternal, foetal, and neonatal outcomes. Regarding drug‐related adverse events, random‐effects analyses showed a significant effect of IPTp‐mefloquine plus cotrimoxazole prophylaxis compared with cotrimoxazole alone only in the case of vomiting (RR 20.88, 95% CI 1.40 to 311.66; 1347 participants; *low‐certainty evidence*). It is important to note that mefloquine plus cotrimoxazole recipients were at 1.92 times greater risk of mother‐to‐child transmission of HIV than the group that received cotrimoxazole alone (RR 1.92, 95% CI 1.13 to 3.25; 1019 participants). A secondary analysis of one of the included trials revealed this finding ([@CD011444-bbs2-0005]).

One trial among HIV‐infected women comparing three doses of IPTp‐mefloquine and cotrimoxazole was underpowered to detect an effect of mefloquine on maternal, foetal, infant, and safety outcomes, except for drug‐related adverse events, which were more frequent in the mefloquine group.

Finally, the single trial conducted in Thailand (where *Plasmodium vivax* coexists) found a significant effect attributable to mefloquine weekly prophylaxis (compared with placebo) only in reducing the risk of maternal peripheral parasitaemia at delivery (RR 0.13, 95% CI 0.05 to 0.33; 339 participants).

Overall completeness and applicability of evidence {#CD011444-sec2-0012}
--------------------------------------------------

Trials were carried out in sub‐Saharan Africa, except for one conducted in Thailand, and were published between 1994 and 2014. Findings evidenced that mefloquine chemoprevention reduces the risk of maternal parasitaemia at delivery in both HIV‐uninfected and HIV‐infected women compared with other antimalarials or placebo. Additionally, in HIV‐infected women, Mefloquine was found to reduce the risk of placental malaria. Results from these trials show fairly consistent clinically important benefits for women and their infants. However, the risk of drug‐related adverse events was increased among mefloquine recipients, and it is notable that mefloquine increased the risk of mother‐to‐child transmission in one trial.

Included trials evaluated two or three IPTp doses of sulfadoxine‐pyrimethamine as per World Health Organization (WHO) recommendations, whereas current evidence suggests that monthly doses may provide a better prophylactic effect ([@CD011444-bbs2-0039]). Additionally, the WHO currently recommends IPTp administration at each scheduled antenatal contact ([@CD011444-bbs2-0068]).

The findings of this review, derived from a variety of sub‐Saharan African settings and comparing mefloquine chemoprevention in pregnancy with varied antimalarial drugs and placebo, may be applied worldwide. Mefloquine is currently recommended as malaria chemoprevention for pregnant women of all gestational ages travelling to malaria‐endemic areas ([@CD011444-bbs2-0025]). This drug is also recommended for treatment of uncomplicated malaria episodes in combination with artesunate ([@CD011444-bbs2-0070]), and a fixed‐dose formulation is available in some malaria‐endemic countries. In 2013, the WHO Evidence Review Group (ERG) on IPTp met to assess evidence obtained from IPTp‐mefloquine trials, and the WHO Malaria Policy Advisory Committee (MPAC) reviewed ERG recommendations and agreed that mefloquine at the 15‐mg/kg dose regimen should not be recommended for IPTp, given its adverse events and poor tolerability ([@CD011444-bbs2-0071]).

Quality of the evidence {#CD011444-sec2-0013}
-----------------------

We assessed the certainty of evidence in this review by using the GRADE approach and presented the evidence in two 'Summary of findings\' tables for efficacy and safety outcomes ([Table 1](#CD011444-tbl-0001){ref-type="table"}; [Table 2](#CD011444-tbl-0002){ref-type="table"}).

For HIV‐uninfected pregnant women, evidence that IPTp‐mefloquine was superior to IPTp‐sulfadoxine‐pyrimethamine in reducing the risk of maternal peripheral parasitaemia and anaemia at delivery was of moderate certainty, and evidence that IPTp‐mefloquine increased drug‐related adverse effects (namely, vomiting and dizziness) compared with IPTp‐sulfadoxine‐pyrimethamine was of high and moderate certainty (respectively). We considered the effects of IPTp‐mefloquine in decreasing placental malaria risk compared with IPTp‐sulfadoxine‐pyrimethamine to be of low certainty because of substantial heterogeneity among trials. Finally, we considered evidence of no effects of mefloquine compared with sulfadoxine‐pyrimethamine on low birth weight and stillbirths and abortions to be of moderate certainty.

For HIV‐infected women, evidence that cotrimoxazole plus IPTp‐mefloquine was superior to cotrimoxazole in reducing the risk of maternal peripheral parasitaemia and anaemia at delivery was of moderate certainty, whereas evidence regarding lack of effect on risk of placental malaria was of high certainty. Evidence of no effects of cotrimoxazole plus IPTp‐mefloquine compared with cotrimoxazole on low birth weight and stillbirths and abortions was of moderate and very low certainty, respectively, because of serious risk of bias of one of the included trials and substantial heterogeneity. Finally, we considered evidence of mefloquine increasing risks of vomiting and dizziness to be of low certainty because heterogeneity among trials was substantial and the 95% CI was wide.

Potential biases in the review process {#CD011444-sec2-0014}
--------------------------------------

It seems unlikely that we have missed any trials examining mefloquine for prevention of malaria in pregnant women.

Agreements and disagreements with other studies or reviews {#CD011444-sec2-0015}
----------------------------------------------------------

A previous Cochrane Review on drugs for preventing malaria in pregnant women in endemic areas analyzed the effects of mefloquine for prevention of malaria ([@CD011444-bbs2-0051]). Our results are consistent with those previously reported but include more trials and thus may be more robust.

The findings of this Cochrane Review are also consistent with those of a previous systematic review assessing the safety and tolerability of mefloquine in pregnancy ([@CD011444-bbs2-0034]).

Authors\' conclusions {#CD011444-sec1-0007}
=====================

In past decades, many clinical trials have tested mefloquine chemoprevention to prevent malaria and its consequences in pregnant women.For HIV‐uninfected pregnant women, IPTp‐mefloquine better reduces malaria effects compared with IPTp‐sulfadoxine‐pyrimethamine, but the drug is worse tolerated than sulfadoxine‐pyrimethamine. For HIV‐infected pregnant women, IPTp‐mefloquine added to cotrimoxazole prophylaxis reduces the risk of important malaria consequences better than cotrimoxazole alone, but drug tolerability constitutes a health issue.The data show that mefloquine is an efficacious and safe antimalarial drug in terms of pregnancy outcomes for prevention of malaria in pregnancy. However, the high proportion of mefloquine‐related adverse events constitutes an important barrier to its effectiveness for malaria preventive treatment in pregnant women.Mefloquine efficacy to prevent malaria effects in pregnancy is well established. Future research should concentrate on finding a dose that would provide the same antimalarial beneficial effects while reducing its drug‐related adverse events, especially as weekly prophylaxis (for example, at a dose of 5 mg/kg) for HIV‐uninfected women living in areas of high sulfadoxine‐pyrimethamine resistance. Researchers also should further examine findings on the two‐fold increased risk of mother‐to‐child transmission of HIV among mefloquine recipients.

We thank David Sinclair and Ragna Boerma for their contributions to protocol development and analysis inputs for this review. We thank Valérie Briand, Michel Cot, and Lise Denoeud‐Ndam for contributing unpublished data. Finally, we thank Vittoria Lutje, Anne‐Marie Stephani, and Paul Garner from the Cochrane Infectious Diseases Group, and Marta Roqué from the Iberoamerican Cochrane Centre. for support and help provided throughout all phases of development of this Cochrane Review.
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Comparison 1Mefloquine versus sulfadoxine‐pyrimethamineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Clinical malaria episodes during pregnancy](#CD011444-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 1 Clinical malaria episodes during pregnancy.2Rate Ratio (Fixed, 95% CI)0.83 \[0.65, 1.05\][2 Maternal peripheral parasitaemia at delivery](#CD011444-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 2 Maternal peripheral parasitaemia at delivery.25455Risk Ratio (M‐H, Fixed, 95% CI)0.65 \[0.48, 0.86\][3 Placental malaria](#CD011444-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 3 Placental malaria.24668Risk Ratio (M‐H, Random, 95% CI)1.04 \[0.58, 1.86\][4 Mean haemoglobin at delivery](#CD011444-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 4 Mean haemoglobin at delivery.25588Mean Difference (IV, Fixed, 95% CI)0.10 \[0.01, 0.19\][5 Maternal anaemia at delivery](#CD011444-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 5 Maternal anaemia at delivery.25469Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.76, 0.94\][6 Severe maternal anaemia at delivery](#CD011444-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 6 Severe maternal anaemia at delivery.25469Risk Ratio (M‐H, Random, 95% CI)0.93 \[0.58, 1.48\][7 Cord blood parasitaemia](#CD011444-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 7 Cord blood parasitaemia.25309Risk Ratio (M‐H, Random, 95% CI)0.44 \[0.13, 1.46\][8 Cord blood anaemia](#CD011444-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 8 Cord blood anaemia.14006Risk Ratio (M‐H, Fixed, 95% CI)1.04 \[0.87, 1.23\][9 Mean birth weight](#CD011444-fig-00109){ref-type="fig"}Analysis 1.9Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 9 Mean birth weight.25241Mean Difference (IV, Fixed, 95% CI)2.52 \[‐25.66, 30.69\][10 Low birth weight](#CD011444-fig-00110){ref-type="fig"}Analysis 1.10Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 10 Low birth weight.25641Risk Ratio (M‐H, Random, 95% CI)0.95 \[0.78, 1.17\][11 Low birth weight by gravidity](#CD011444-fig-00111){ref-type="fig"}Analysis 1.11Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 11 Low birth weight by gravidity.25641Risk Ratio (M‐H, Fixed, 95% CI)0.97 \[0.84, 1.13\]11.1 Primigravidae21576Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.80, 1.30\]11.2 Multigravidae24065Risk Ratio (M‐H, Fixed, 95% CI)0.94 \[0.78, 1.14\][12 Prematurity](#CD011444-fig-00112){ref-type="fig"}Analysis 1.12Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 12 Prematurity.24640Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[0.76, 1.40\][13 Malaria in first year of life](#CD011444-fig-00113){ref-type="fig"}Analysis 1.13Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 13 Malaria in first year of life.1Rate Ratio (Fixed, 95% CI)0.97 \[0.82, 1.15\][14 Hospital admissions in first year of life](#CD011444-fig-00114){ref-type="fig"}Analysis 1.14Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 14 Hospital admissions in first year of life.1Rate Ratio (Fixed, 95% CI)0.93 \[0.75, 1.17\][15 SAEs during pregnancy](#CD011444-fig-00115){ref-type="fig"}Analysis 1.15Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 15 SAEs during pregnancy.14674Risk Ratio (M‐H, Fixed, 95% CI)0.98 \[0.81, 1.20\][16 Stillbirths and abortions](#CD011444-fig-00116){ref-type="fig"}Analysis 1.16Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 16 Stillbirths and abortions.26219Risk Ratio (M‐H, Fixed, 95% CI)1.20 \[0.91, 1.58\][17 Congenital malformations](#CD011444-fig-00117){ref-type="fig"}Analysis 1.17Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 17 Congenital malformations.25931Risk Ratio (M‐H, Random, 95% CI)1.10 \[0.51, 2.37\][18 Maternal mortality](#CD011444-fig-00118){ref-type="fig"}Analysis 1.18Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 18 Maternal mortality.26219Risk Ratio (M‐H, Random, 95% CI)2.41 \[0.27, 21.23\][19 Neonatal mortality](#CD011444-fig-00119){ref-type="fig"}Analysis 1.19Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 19 Neonatal mortality.26134Risk Ratio (M‐H, Fixed, 95% CI)0.98 \[0.67, 1.43\][20 Infant mortality](#CD011444-fig-00120){ref-type="fig"}Analysis 1.20Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 20 Infant mortality.1Rate Ratio (Fixed, 95% CI)1.00 \[0.66, 1.52\][21 AEs: vomiting](#CD011444-fig-00121){ref-type="fig"}Analysis 1.21Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 21 AEs: vomiting.26272Risk Ratio (M‐H, Fixed, 95% CI)4.76 \[4.13, 5.49\][22 AEs: fatigue/weakness](#CD011444-fig-00122){ref-type="fig"}Analysis 1.22Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 22 AEs: fatigue/weakness.26272Risk Ratio (M‐H, Random, 95% CI)4.62 \[1.80, 11.85\][23 AEs: dizziness](#CD011444-fig-00123){ref-type="fig"}Analysis 1.23Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 23 AEs: dizziness.26272Risk Ratio (M‐H, Random, 95% CI)4.21 \[3.36, 5.27\][24 AEs: headache](#CD011444-fig-00124){ref-type="fig"}Analysis 1.24Comparison 1 Mefloquine versus sulfadoxine‐pyrimethamine, Outcome 24 AEs: headache.26272Risk Ratio (M‐H, Random, 95% CI)0.70 \[0.25, 1.94\]

Comparison 2Mefloquine plus cotrimoxazole versus cotrimoxazoleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Clinical malaria episodes during pregnancy](#CD011444-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 1 Clinical malaria episodes during pregnancy.1Rate Ratio (Fixed, 95% CI)0.76 \[0.33, 1.76\][2 Maternal peripheral parasitaemia at delivery (PCR)](#CD011444-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 2 Maternal peripheral parasitaemia at delivery (PCR).2989Risk Ratio (M‐H, Fixed, 95% CI)0.52 \[0.30, 0.93\][3 Placental malaria (blood smear)](#CD011444-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 3 Placental malaria (blood smear).21144Risk Ratio (M‐H, Fixed, 95% CI)0.51 \[0.29, 0.89\][4 Placental malaria (PCR)](#CD011444-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 4 Placental malaria (PCR).2977Risk Ratio (M‐H, Fixed, 95% CI)0.28 \[0.14, 0.57\][5 Mean haemoglobin at delivery](#CD011444-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 5 Mean haemoglobin at delivery.21167Mean Difference (IV, Random, 95% CI)0.07 \[‐0.32, 0.46\][6 Maternal anaemia at delivery (\< 9.5 g/dL)](#CD011444-fig-00206){ref-type="fig"}Analysis 2.6Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 6 Maternal anaemia at delivery (\< 9.5 g/dL).21197Risk Ratio (M‐H, Fixed, 95% CI)0.94 \[0.73, 1.20\][7 Maternal severe anaemia at delivery](#CD011444-fig-00207){ref-type="fig"}Analysis 2.7Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 7 Maternal severe anaemia at delivery.21167Risk Ratio (M‐H, Fixed, 95% CI)0.93 \[0.41, 2.08\][8 Cord blood parasitaemia](#CD011444-fig-00208){ref-type="fig"}Analysis 2.8Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 8 Cord blood parasitaemia.21166Risk Ratio (M‐H, Fixed, 95% CI)0.33 \[0.03, 3.13\][9 Mean birth weight](#CD011444-fig-00209){ref-type="fig"}Analysis 2.9Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 9 Mean birth weight.21220Mean Difference (IV, Random, 95% CI)‐25.75 \[‐86.99, 35.49\][10 Low birth weight](#CD011444-fig-00210){ref-type="fig"}Analysis 2.10Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 10 Low birth weight.21220Risk Ratio (M‐H, Fixed, 95% CI)1.20 \[0.89, 1.60\][11 Prematurity](#CD011444-fig-00211){ref-type="fig"}Analysis 2.11Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 11 Prematurity.2824Risk Ratio (M‐H, Random, 95% CI)1.07 \[0.58, 1.96\][12 SAEs during pregnancy](#CD011444-fig-00212){ref-type="fig"}Analysis 2.12Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 12 SAEs during pregnancy.21347Risk Ratio (M‐H, Fixed, 95% CI)0.69 \[0.50, 0.95\][13 Spontaneous abortions and stillbirths](#CD011444-fig-00213){ref-type="fig"}Analysis 2.13Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 13 Spontaneous abortions and stillbirths.21347Risk Ratio (M‐H, Random, 95% CI)1.12 \[0.42, 2.98\][14 Congenital malformations](#CD011444-fig-00214){ref-type="fig"}Analysis 2.14Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 14 Congenital malformations.21312Risk Ratio (M‐H, Fixed, 95% CI)0.61 \[0.22, 1.67\][15 Maternal mortality](#CD011444-fig-00215){ref-type="fig"}Analysis 2.15Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 15 Maternal mortality.21347Risk Ratio (M‐H, Fixed, 95% CI)0.51 \[0.13, 2.01\][16 Neonatal mortality](#CD011444-fig-00216){ref-type="fig"}Analysis 2.16Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 16 Neonatal mortality.21239Risk Ratio (M‐H, Fixed, 95% CI)1.32 \[0.65, 2.69\][17 Mother‐to‐child transmission HIV](#CD011444-fig-00217){ref-type="fig"}Analysis 2.17Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 17 Mother‐to‐child transmission HIV.21019Risk Ratio (M‐H, Fixed, 95% CI)1.92 \[1.13, 3.25\][18 AEs: vomiting](#CD011444-fig-00218){ref-type="fig"}Analysis 2.18Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 18 AEs: vomiting.21347Risk Ratio (M‐H, Random, 95% CI)20.88 \[1.40, 311.66\][19 AEs: fatigue/weakness](#CD011444-fig-00219){ref-type="fig"}Analysis 2.19Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 19 AEs: fatigue/weakness.21347Risk Ratio (M‐H, Random, 95% CI)2.95 \[0.26, 32.93\][20 AEs: dizziness](#CD011444-fig-00220){ref-type="fig"}Analysis 2.20Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 20 AEs: dizziness.21347Risk Ratio (M‐H, Random, 95% CI)16.34 \[0.39, 684.99\][21 AEs: headache](#CD011444-fig-00221){ref-type="fig"}Analysis 2.21Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 21 AEs: headache.21347Risk Ratio (M‐H, Random, 95% CI)0.76 \[0.28, 2.10\]

Comparison 3Mefloquine versus cotrimoxazoleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Maternal peripheral parasitaemia at delivery (PCR)](#CD011444-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Mefloquine versus cotrimoxazole, Outcome 1 Maternal peripheral parasitaemia at delivery (PCR).198Risk Ratio (M‐H, Fixed, 95% CI)0.21 \[0.03, 1.72\][2 Placental malaria (PCR)](#CD011444-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Mefloquine versus cotrimoxazole, Outcome 2 Placental malaria (PCR).194Risk Ratio (M‐H, Fixed, 95% CI)0.73 \[0.13, 4.15\][3 Placental malaria (blood smear)](#CD011444-fig-00303){ref-type="fig"}Analysis 3.3Comparison 3 Mefloquine versus cotrimoxazole, Outcome 3 Placental malaria (blood smear).1108Risk Ratio (M‐H, Fixed, 95% CI)0.35 \[0.01, 8.30\][4 Mean haemoglobin at delivery](#CD011444-fig-00304){ref-type="fig"}Analysis 3.4Comparison 3 Mefloquine versus cotrimoxazole, Outcome 4 Mean haemoglobin at delivery.1100Mean Difference (IV, Fixed, 95% CI)‐0.10 \[‐0.67, 0.47\][5 Maternal anaemia at delivery (\< 9.5 g/dL)](#CD011444-fig-00305){ref-type="fig"}Analysis 3.5Comparison 3 Mefloquine versus cotrimoxazole, Outcome 5 Maternal anaemia at delivery (\< 9.5 g/dL).1100Risk Ratio (M‐H, Fixed, 95% CI)0.90 \[0.26, 3.16\][6 Mean birth weight](#CD011444-fig-00306){ref-type="fig"}Analysis 3.6Comparison 3 Mefloquine versus cotrimoxazole, Outcome 6 Mean birth weight.1120Mean Difference (IV, Fixed, 95% CI)‐102.0 \[‐255.52, 51.52\][7 Low birth weight](#CD011444-fig-00307){ref-type="fig"}Analysis 3.7Comparison 3 Mefloquine versus cotrimoxazole, Outcome 7 Low birth weight.1120Risk Ratio (M‐H, Fixed, 95% CI)1.52 \[0.56, 4.13\][8 Prematurity](#CD011444-fig-00308){ref-type="fig"}Analysis 3.8Comparison 3 Mefloquine versus cotrimoxazole, Outcome 8 Prematurity.1125Risk Ratio (M‐H, Fixed, 95% CI)1.08 \[0.33, 3.56\][9 SAEs during pregnancy](#CD011444-fig-00309){ref-type="fig"}Analysis 3.9Comparison 3 Mefloquine versus cotrimoxazole, Outcome 9 SAEs during pregnancy.1140Risk Ratio (M‐H, Fixed, 95% CI)1.06 \[0.28, 4.07\][10 Stillbirths](#CD011444-fig-00310){ref-type="fig"}Analysis 3.10Comparison 3 Mefloquine versus cotrimoxazole, Outcome 10 Stillbirths.1139Risk Ratio (M‐H, Fixed, 95% CI)4.30 \[0.49, 37.49\][11 Spontaneous abortions](#CD011444-fig-00311){ref-type="fig"}Analysis 3.11Comparison 3 Mefloquine versus cotrimoxazole, Outcome 11 Spontaneous abortions.1139Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.07, 16.84\][12 Congenital malformations](#CD011444-fig-00312){ref-type="fig"}Analysis 3.12Comparison 3 Mefloquine versus cotrimoxazole, Outcome 12 Congenital malformations.1139Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.16, 7.41\][13 Maternal mortality](#CD011444-fig-00313){ref-type="fig"}Analysis 3.13Comparison 3 Mefloquine versus cotrimoxazole, Outcome 13 Maternal mortality.1139Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][14 Neonatal mortality](#CD011444-fig-00314){ref-type="fig"}Analysis 3.14Comparison 3 Mefloquine versus cotrimoxazole, Outcome 14 Neonatal mortality.1129Risk Ratio (M‐H, Fixed, 95% CI)1.05 \[0.07, 16.39\][15 Infant deaths after 7 days](#CD011444-fig-00315){ref-type="fig"}Analysis 3.15Comparison 3 Mefloquine versus cotrimoxazole, Outcome 15 Infant deaths after 7 days.1129Risk Ratio (M‐H, Fixed, 95% CI)2.10 \[0.19, 22.54\][16 AEs: vomiting](#CD011444-fig-00316){ref-type="fig"}Analysis 3.16Comparison 3 Mefloquine versus cotrimoxazole, Outcome 16 AEs: vomiting.1139Risk Ratio (M‐H, Fixed, 95% CI)13.43 \[3.31, 54.54\][17 AEs: fatigue/weakness](#CD011444-fig-00317){ref-type="fig"}Analysis 3.17Comparison 3 Mefloquine versus cotrimoxazole, Outcome 17 AEs: fatigue/weakness.1139Risk Ratio (M‐H, Fixed, 95% CI)6.99 \[1.64, 29.81\][18 AEs: dizziness](#CD011444-fig-00318){ref-type="fig"}Analysis 3.18Comparison 3 Mefloquine versus cotrimoxazole, Outcome 18 AEs: dizziness.1139Risk Ratio (M‐H, Fixed, 95% CI)52.60 \[3.26, 848.24\][19 AEs: headache](#CD011444-fig-00319){ref-type="fig"}Analysis 3.19Comparison 3 Mefloquine versus cotrimoxazole, Outcome 19 AEs: headache.1139Risk Ratio (M‐H, Fixed, 95% CI)0.21 \[0.01, 4.39\]

Comparison 4Mefloquine versus placeboOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Maternal peripheral parasitaemia during pregnancy](#CD011444-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Mefloquine versus placebo, Outcome 1 Maternal peripheral parasitaemia during pregnancy.1339Risk Ratio (M‐H, Fixed, 95% CI)0.13 \[0.05, 0.33\][2 Placental malaria](#CD011444-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Mefloquine versus placebo, Outcome 2 Placental malaria.1220Risk Ratio (M‐H, Fixed, 95% CI)0.14 \[0.01, 2.68\][3 Mean birth weight](#CD011444-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 Mefloquine versus placebo, Outcome 3 Mean birth weight.1290Mean Difference (IV, Fixed, 95% CI)‐80.0 \[‐184.65, 24.65\][4 Low birth weight](#CD011444-fig-00404){ref-type="fig"}Analysis 4.4Comparison 4 Mefloquine versus placebo, Outcome 4 Low birth weight.1290Risk Ratio (M‐H, Fixed, 95% CI)1.39 \[0.78, 2.48\][5 Prematurity](#CD011444-fig-00405){ref-type="fig"}Analysis 4.5Comparison 4 Mefloquine versus placebo, Outcome 5 Prematurity.1199Risk Ratio (M‐H, Fixed, 95% CI)0.48 \[0.15, 1.53\][6 Stillbirths](#CD011444-fig-00406){ref-type="fig"}Analysis 4.6Comparison 4 Mefloquine versus placebo, Outcome 6 Stillbirths.1311Risk Ratio (M‐H, Fixed, 95% CI)2.63 \[0.86, 8.08\][7 Spontaneous abortions](#CD011444-fig-00407){ref-type="fig"}Analysis 4.7Comparison 4 Mefloquine versus placebo, Outcome 7 Spontaneous abortions.1311Risk Ratio (M‐H, Fixed, 95% CI)0.48 \[0.04, 5.22\][8 Congenital malformations](#CD011444-fig-00408){ref-type="fig"}Analysis 4.8Comparison 4 Mefloquine versus placebo, Outcome 8 Congenital malformations.1311Risk Ratio (M‐H, Fixed, 95% CI)3.82 \[0.43, 33.83\][9 Maternal mortality](#CD011444-fig-00409){ref-type="fig"}Analysis 4.9Comparison 4 Mefloquine versus placebo, Outcome 9 Maternal mortality.1339Risk Ratio (M‐H, Fixed, 95% CI)2.95 \[0.12, 71.85\][10 Infant mortality](#CD011444-fig-00410){ref-type="fig"}Analysis 4.10Comparison 4 Mefloquine versus placebo, Outcome 10 Infant mortality.1288Risk Ratio (M‐H, Fixed, 95% CI)1.04 \[0.63, 1.74\]

In the protocol, we indicated that for the safety evaluation of mefloquine in pregnancy, we would include studies that used mefloquine to prevent malaria in pregnant women travelling to malaria‐endemic areas. However, evaluation of mefloquine safety compared with the safety of other antimalarials was not possible because of the study design employed by retrieved studies. Consequently, no observational studies met the inclusion criteria and only randomized controlled trials met the inclusion criteria of this review.

In the protocol, we listed neonatal morbidity in the first 28 days of life as an analysis outcome. Similarly, we listed mean haemoglobin and maternal anaemia during pregnancy were as outcomes. However, the included trials did not report on these effects; consequently, we were unable to perform the analyses.

One included trial reported an unexpected increased risk of mother‐to‐child transmission (MTCT) of HIV associated with IPTp‐mefloquine. Given the clinical relevance of this finding, we included the frequency of MTCT of HIV as an outcome of the analysis.

Characteristics of included studies \[ordered by study ID\] {#CD011444-sec2-0019}
===========================================================

[@CD011444-bbs2-0001]MethodsTrial design: open‐label, randomized, 2‐arm trial of 2 doses of IPTp\
Follow‐up: the second IPTp dose was administered from 30 weeks of gestation and at least 1 month after administration of the first dose. Women were visited at home, at delivery, and until 6 weeks after the end of pregnancy.\
Adverse event (AE) monitoring: AEs were recorded via an open‐labelled questionnaire during visits at home occurring within 1 week after each IPTp intake.ParticipantsNumbers of participants randomized: 802 (IPTp‐mefloquine), 799 (IPTp‐sulfadoxine‐pyrimethamine)\
Inclusion criteria: HIV‐uninfected women of all gravidities at 16 to 28 weeks of gestation who had no history of a neurological or psychiatric disorder and who had not previously used sulfadoxine‐pyrimethamine or mefloquine nor reported having adverse reactions to medications containing sulfa.\
Exclusion criteria: pregnant women not meeting inclusion criteria.InterventionsTwo doses of IPTp with sulfadoxine‐pyrimethamine (1500 mg of sulfadoxine and 75 mg of pyrimethamine per dose)Two doses of IPTp with mefloquine (15 mg/kg per dose; Mepha)OutcomesMaternal peripheral parasitaemia at deliveryPlacental malaria (presence of asexual stage parasites in blood smear)Maternal anaemia at delivery (defined by haemoglobin \< 10 g/dL)Mean haemoglobin at deliveryClinical malaria episodes during pregnancyCord blood parasitaemiaMean birth weightLow birth weight ratesPrematurity ratesSpontaneous abortion (expulsion of a foetus at \< 28 weeks of gestation) ratesStillbirth rates (delivery of a dead child at \< 28 weeks of gestation)Congenital malformation ratesMaternal mortalityNeonatal mortalityFrequency of adverse events: vomiting, headache, weakness, and dizzinessNotesCountry: Benin\
Setting: antenatal care clinics from Ouidah,a semi‐rural town\
Transmission: perennial with seasonal peaks\
Resistance: in 2005, rates of sulfadoxine‐pyrimethamine and mefloquine resistance in vivo in children \< 5 years of age were estimated to be 50% and 2.5% by day 28 of treatment, respectively.\
Dates: 2005 to 2008\
Funding: Fonds de Solidarité Prioritaire (French Ministry of Foreign Affairs; project no. 2006--22); Institut de Recherche pour le Développement; Fondation pour la Recherche Médicale (grant FDM20060907976 to V.B.); Fondation de France; and Fondation Mérieux***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskQuote: \"Randomization of subjects was stratified according to maternity clinic and gravidity\".Allocation concealment (selection bias)High riskAllocation was not concealed.Blinding of participants and personnel (performance bias) All outcomesHigh riskNo blinding was reported, and safety outcomes are likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) EfficacyLow riskNo blinding of outcome assessment was reported, but the review authors judge that the efficacy outcome measurement is not likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) SafetyHigh riskNo blinding of outcome assessment was reported; thus the review authors judge that the safety outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesLow riskMissing outcome data were balanced in numbers across intervention groups, and similar reasons for missing data were reported across groups.Selective reporting (reporting bias)Low riskThe study protocol is not available, but it is clear that published reports describe all expected outcomes, including those that were prespecified.Other biasLow riskThe study appears to be free of other sources of bias.[@CD011444-bbs2-0002]MethodsTrial design: randomized, open‐label trial of 3 doses of IPTp\
Follow‐up: 3 scheduled IPTp administrations with at least a 1‐month interval between them. IPTp‐mefloquine administration and provision of cotrimoxazole. Clinical and adherence information, complete blood count, CD4 count, malaria screening, and treatment of malaria.\
At delivery: blood smears from placenta and umbilical cords and evaluation of newborns. Infant evaluation at 6 weeks, 4 months, and 2 months after weaning\
Adverse event (AE) monitoring: self‐reporting of all AEs. All adverse events were recorded at each visit. In addition, direct observation of early adverse reactions to mefloquine within 30 minutes after supervised intake was noted and later reactions were collected by phone the same day/evening or on the next day. Medical examination was performed 2 weeks after cotrimoxazole initiation to search for cutaneous reactions. An independent data and safety monitoring board reviewed all SAEs.ParticipantsNumbers of participants randomized: 146 (cotrimoxazole), 146 (cotrimoxazole+mefloquine)\
Inclusion criteria: HIV‐infected pregnant women of all gravidities aged \> 18 years, living permanently in the study area, between 16 and 28 weeks of gestation; last dosage of IPTp taken 1 month before enrolment; women requiring antimalarial treatment enrolled at least 2 weeks after completion of treatment\
Exclusion criteria: history of neuropsychiatric disorder; severe kidney or liver disease; serious adverse reaction to mefloquine, sulfa drugs, or quinineInterventions[IPTp with mefloquine plus cotrimoxazole]{.ul}\
15 mg/kg single dose (250 mg tablet, Lariam, Roche), 3 doses 1 month apartDaily dose of 800 mg sulfamethoxazole and 160 mg trimethoprim\
[Cotrimoxazole]{.ul}\
Daily dose of 800 mg sulfamethoxazole and 160 mg trimethoprim\
All study participants were given LLITNs and daily supplementation with 100 mg ferrous sulphate and 5 mg folic acid.\
The first dose was given at ≥ 16 weeks of gestation.\
All women were observed for 30 minutes following IPTp administration. Women vomiting within the first 30 minutes were given a second full IPTp dose.\
Asymptomatic women and women with low parasitaemia (\< 1000 parasites/µL) were treated by the IPTp‐mefloquine dose in the mefloquine groups. Otherwise, women received artemether‐lumefantrine or oral quinine. Those with severe malaria were treated with intravenous quinine.OutcomesMaternal peripheral parasitaemia at delivery (PCR)Placental parasitaemia at delivery (blood smear and PCR)Mean maternal haemoglobin at deliveryMaternal anaemia (\< 9.5 g/dL) at deliveryCord blood parasitaemia at deliveryMean birth weightLow birth weight (\< 2500 g)PrematuritySerious adverse events (SAEs) during pregnancySpontaneous abortions (\< 28 weeks)Stillbirths (≥ 28 weeks of gestation)Congenital malformations (\< 28 weeks of gestation)Early neonatal mortality (\< 7 days)Neonatal mortalityInfant deaths after 7 daysVomitingDizzinessHeadacheFatigue/weaknessNotesCountry: Benin\
Setting: 5 urban hospitals with PMTCT programmes\
Malaria transmission: intense and perennial transmission, with peaks during rainy seasons\
Resistance: increasing risk of resistance to sulfa drugs. Parasite resistance to cotrimoxazole\
Dates: 2009 to 2012\
Funding: Sidaction Grant AI19‐3‐01528***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskQuote: \"Randomization was stratified according to the study site and the number of previous pregnancies\".Allocation concealment (selection bias)Low riskQuote: \"The study coordination center retained the master list and assigned treatment by phone\".Blinding of participants and personnel (performance bias) All outcomesHigh riskThe trial blinded only the microscopist who evaluated blood smears.Blinding of outcome assessment (detection bias) EfficacyLow riskNo blinding of outcome assessment was reported, but the review authors judge that the efficacy outcome measurement is not likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) SafetyHigh riskNo blinding of outcome assessment was reported; thus the review authors judge that the safety outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesLow riskMissing outcome data were balanced in numbers across groups.Selective reporting (reporting bias)Low riskProtocol was not available, but published report describes all expected outcomes including those prespecified.Other biasLow riskThe study appears to be free of other sources of bias.[@CD011444-bbs2-0003]MethodsTrial design: randomized, open‐label trial of 3 doses of IPTp\
Follow‐up: 3 scheduled IPTp administrations with at least a 1‐month interval between them. IPTp‐mefloquine administration and provision of cotrimoxazole. Clinical and adherence information, complete blood count, CD4 count, malaria screening, and treatment of malaria.\
At delivery: blood smears from placenta and umbilical cords and evaluation of newborns. Infant evaluation at 6 weeks, 4 months, and 2 months after weaning\
Adverse event (AE) monitoring: self‐reporting of all AEs. All adverse events were recorded at each visit. In addition, direct observation of early adverse reactions to mefloquine within 30 minutes after supervised intake was noted and later reactions were collected by phone the same day/evening or on the next day. Medical examination was performed 2 weeks after cotrimoxazole initiation to search for cutaneous reactions. An independent data and safety monitoring board reviewed all SAEs.ParticipantsNumbers of participants randomized: 72 (cotrimoxazole), 68 (mefloquine)\
Inclusion criteria: HIV‐infected pregnant women of all gravidities aged \> 18 years, living permanently in the study area, between 16 and 28 weeks of gestation, last dosage of IPTp taken 1 month before enrolment, women requiring antimalarial treatment enrolled at least 2 weeks after completion of treatment\
Exclusion criteria: history of neuropsychiatric disorder; severe kidney or liver disease; serious adverse reaction to mefloquine, sulfa drugs, or quinineInterventions[IPTp with mefloquine]{.ul}\
15 mg/kg single dose (250 mg tablet, Lariam, Roche)Three doses 1 month apart\
Cotrimoxazole\
Daily dose of 800 mg sulfamethoxazole and 160 mg trimethoprim\
All study participants were given LLITNs and daily supplementation with 100 mg ferrous sulphate and 5 mg folic acid.\
The first dose was given at ≥ 16 weeks of gestation.\
All women were observed for 30 minutes following IPTp administration. Women vomiting within the first 30 minutes were given a second full IPTp dose.\
Asymptomatic women and women with low parasitaemia (\< 1000 parasites/µL) in the mefloquine groups were treated by the IPTp‐mefloquine dose. Otherwise, women received artemether‐lumefantrine or oral quinine. Thos with severe malaria were treated with intravenous quinine.OutcomesMaternal peripheral parasitaemia at delivery (PCR)Placental parasitaemia at delivery (blood smear and PCR)Mean maternal haemoglobin at deliveryMaternal anaemia (\< 9.5 g/dL) at deliveryCord blood parasitaemia at deliveryMean birth weightLow birth weight (\< 2500 g)PrematuritySerious adverse events (SAEs) during pregnancySpontaneous abortions (\< 28 weeks)Stillbirths (≥ 28 weeks of gestation)Congenital malformations (\< 28 weeks of gestation)Early neonatal mortality (\< 7 days)Neonatal mortalityInfant deaths after 7 daysVomitingDizzinessHeadacheFatigue/weaknessNotesCountry: Benin\
Setting: 5 urban hospitals with PMTCT programmes\
Malaria transmission: intense and perennial transmission, with peaks during rainy seasons\
Resistance: increasing risk of resistance to sulfa drugs. Parasite resistance to cotrimoxazole\
Dates: 2009 to 2012\
Funding: Sidaction Grant AI19‐3‐01528***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskQuote: \"Randomization was stratified according to the study site and the number of previous pregnancies\".Allocation concealment (selection bias)Low riskQuote: \"The study coordination center retained the master list and assigned treatment by phone\".Blinding of participants and personnel (performance bias) All outcomesHigh riskThe trial blinded only the microscopist who evaluated blood smears.Blinding of outcome assessment (detection bias) EfficacyLow riskNo blinding of outcome assessment was reported, but the review authors judge that the efficacy outcome measurement is not likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) SafetyHigh riskNo blinding of outcome assessment was reported; thus the review authors judge that the safety outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesLow riskMissing outcome data were balanced in numbers across groups.Selective reporting (reporting bias)Low riskProtocol was not available, but published report describes all expected outcomes including those prespecified.Other biasLow riskThe study appears to be free of other sources of bias.[@CD011444-bbs2-0004]MethodsTrial design: open‐label, randomized, 3‐arm trial of 2 doses of IPTp\
Follow‐up: at each scheduled and unscheduled visit, a standardized symptom questionnaire was completed, as were blood smears for malaria parasites, and haemoglobin if symptoms and/or signs were suggestive of malaria. At delivery, blood samples were collected for haematological and parasitological evaluation. Weighting of newborns and gestational age at birth were recorded. Malaria parasite was determined 6 weeks after the end of pregnancy.\
Adverse event monitoring: home visits by field workers were done 2 days after IPTp administration to assess drug tolerability.\
Solicited and unsolicited adverse events (AEs) were assessed. The former were assessed by directed questioning regarding malaria‐related signs and symptoms during unscheduled visits, whereas the latter were assessed through open questioning during scheduled visits.ParticipantsNumbers of participants randomized: 1578 (sulfadoxine‐pyrimethamine), 1580 (mefloquine full dose), 1591 (mefloquine split)\
Inclusion criteria: HIV‐uninfected women of all gravidities attending the antenatal care clinic for the first time, did not receive IPTp during current pregnancy, permanent residence in the study area, gestational age of ≤ 28 weeks\
Exclusion criteria: HIV‐positive; history of allergy to sulfa drugs or mefloquine; history of severe renal, hepatic, psychiatric, or neurological disease; mefloquine or halofantrine treatment in the preceding 4 weeks; participating in other intervention studiesInterventions[IPTp with sulfadoxine‐pyrimethamine, 3 tablets]{.ul}\
500 mg/25 mgTwo doses 1 month apart\
[IPTp with mefloquine]{.ul}\
15 mg/kg given once as a full dose (250‐mg tablets)Two doses 1 month apart\
[IPTp with mefloquine (split dose)]{.ul}\
15 mg/kg given as a split dose over 2 days (250‐mg tablets)Two doses 1 month apart\
All study participants were given LLITNs.\
The first dose was given at \> 13 weeks of gestation.\
All women were observed for 60 minutes following IPT administration. Women vomiting within the first 30 minutes were given a second full IPT dose, and those vomiting 30 to 60 minutes after drug intake were given a half replacement dose.\
Uncomplicated malaria episodes were treated with oral quinine (first trimester) or artemether‐lumefantrine (second and third trimesters); severe malaria episodes were treated with parenteral quinine.OutcomesMaternal peripheral parasitaemia at deliveryPlacental parasitaemia at deliveryMean maternal haemoglobin at deliveryMaternal anaemia (\< 10 g/dL) at deliveryClinical malaria episodes during pregnancyCord blood parasitaemia at deliveryCord blood anaemiaMean birth weightLow birth weight (\< 2500 g)Low birth weight by gravidityPrematurityMalaria in first year of lifeHospital admissions in first year of lifeMalaria in first year of life (infant morbidity)Hospital admissions in first year of life (infant morbidity)Serious adverse events (SAEs) during pregnancySpontaneous abortions (\< 20 complete weeks of gestation)Stillbirths (\> 20 complete weeks of gestation)Congenital malformationsMaternal mortalityNeonatal mortalityInfant mortalityVomitingHeadacheFatigue/weaknessDizzinessNotesCountry: Tanzania, Mozambique, Benin, and Gabon\
Setting: antenatal care clinics\
Transmission: mesoendemic in Tanzania and Mozambique, hyperendemic in Benin and Gabon\
Resistance: resistance to sulfadoxine‐pyrimethamine due to long‐term sulfadoxine‐pyrimethamine for IPTp\
Dates: 2009 to 2013\
Funding: this study was funded by the European Developing Countries Clinical Trials Partnership (EDCTP; IP.2007.31080.002), the Malaria in Pregnancy Consortium, and the Instituto de Salud Carlos III (PI08/0564), in Spain. RG and MR were partially supported by grants from the Spanish Ministry of Health (ref. CM07/0015 and CM11/00278, respectively). The CISM receives core funding from the Spanish Agency for International Cooperation (AECID). LLITNs (Permanet) were donated by Vestergaard Frandsen.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"The allocation of the participants to the study arms was done centrally by randomization stratified by country according to a 1:1:1 scheme. The sponsor's institution biostatistician produced the computer‐generated randomization list for each recruiting site\".Allocation concealment (selection bias)Low riskQuote: \"Treatment allocation for each participant was concealed in opaque sealed envelopes that were opened only after recruitment. Study participants were assigned a unique study number linked to the allocated treatment group\".Blinding of participants and personnel (performance bias) All outcomesHigh riskQuote: \"The study was designed as an open‐label, randomized, three‐arm trial to compare two‐dose mefloquine with two‐dose SP for IPTp\".Blinding of outcome assessment (detection bias) EfficacyLow riskNo blinding of outcome assessment was reported, but the review authors judge that the efficacy outcome measurement is not likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) SafetyHigh riskNo blinding of outcome assessment was reported; thus the review authors judge that the safety outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesLow riskAll excluded participants, at any stage of the trial, are counted in the flow chart (both ITT and ATP cohorts). Missing outcome data were balanced in numbers across groups.Selective reporting (reporting bias)Low riskNot observed. Protocol availableOther biasLow riskThe study appears to be free of other sources of bias.[@CD011444-bbs2-0005]MethodsTrial design: individually randomized, double‐blind, placebo‐controlled trial of 3 doses of IPTp\
Follow‐up: at each scheduled and unscheduled visit, a standardized symptom questionnaire was completed, as were blood smears for malaria parasites, and haemoglobin if symptoms and/or signs were suggestive of malaria. On a monthly basis, adherence to cotrimoxazole and LLITN was assessed. At delivery, blood samples were collected for haematological and parasitological evaluation with CD4 cell count and HIV viral load. Weighting of newborns and gestational age at birth were recorded. Malaria parasite was determined 6 weeks after the end of pregnancy.\
Adverse event monitoring: home visits by field workers were done 2 days after IPTp administration to assess drug tolerability.\
Solicited and unsolicited adverse events (AEs) were assessed. The former were assessed by directed questioning of malaria‐related signs and symptoms during unscheduled visits, whereas the latter were assessed through open questioning during scheduled visits.ParticipantsNumbers of participants randomized: 537 (placebo+cotrimoxazole), 534 (mefloquine+cotrimoxazole)\
Inclusion criteria: HIV‐infected women of all gravidities attending the antenatal care clinic for the first time, did not receive IPTp during current pregnancy, permanent residence in the study area, gestational age of ≤ 28 weeks, HIV positive\
Exclusion criteria: history of allergy to sulfa drugs or mefloquine; history of severe renal, hepatic, psychiatric, or neurological disease; mefloquine or halofantrine treatment in the preceding 4 weeks; participating in other intervention studiesInterventions[IPTp with mefloquine]{.ul}\
15 mg/kg single dose (maximum dosage would not exceed 1500 mg of mefloquine)Three doses 1 month apart\
[IPTp with placebo]{.ul}\
Identical to mefloquine tablets in shape and colourThree doses 1 month apart\
All study participants had monthly cotrimoxazole prophylaxis (fixed combination 800 mg of trimethroprim and 160 mg of sulfamethoxazole/tablet).\
All study participants were given LLITNs.\
The first dose was given at \> 13 weeks of gestation.\
All women were observed for 60 minutes following IPT administration. Women vomiting within the first 30 minutes were given a second full IPTp dose, and those vomiting 30 to 60 minutes after drug intake were given a half replacement dose.\
Uncomplicated malaria episodes were treated with oral quinine (first trimester) or artemether‐lumefantrine (second and third trimesters); severe malaria episodes were treated with parenteral quinine.OutcomesMaternal peripheral parasitaemia at delivery (PCR)Placental parasitaemia at delivery (blood smear and PCR)Mean maternal haemoglobin at deliveryMaternal anaemia (\< 9.5 g/dL) at deliveryClinical malaria episodes during pregnancyCord blood parasitaemia at deliveryMean birth weightLow birth weight (\< 2500 g)PrematuritySerious adverse events (SAEs) during pregnancySpontaneous abortions (\< 20 complete weeks of gestation)Stillbirths (\> 20 weeks of gestation)Congenital malformationsMaternal mortalityPerinatal mortalityEarly neonatal mortality (\< 7 days)Neonatal mortalityVomitingHeadacheFatigue/weaknessDizzinessNotesCountries: Tanzania, Mozambique, and Kenya\
Setting: antenatal care clinics\
Transmission: mesoendemic in Tanzania and Mozambique, holoendemic in Kenya\
Resistance: resistance to sulfadoxine‐pyrimethamine due to long‐term sulfadoxine‐pyrimethamine for IPTp\
Dates: 2010 to 2013\
Funding: this study was funded by the European Developing Countries Clinical Trials Partnership (EDCTP; IP.2007.31080.002), the Malaria in Pregnancy Consortium, and the Instituto de Salud Carlos III (PI08/0564), in Spain. RG and MR were partially supported by grants from the Spanish Ministry of Health (ref. CM07/0015 and CM11/00278, respectively). The CISM receives core funding from the Spanish Agency for international Cooperation (AECID). LLITNs (Permanet) were donated by Vestergaard Frandsen, and cotrimoxazole tablets (Septrin) by UCB Pharma, in Spain.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"The allocation of the participants to the study arms was done centrally by block randomization (block size of 6) stratified by country\".Allocation concealment (selection bias)Low riskQuote: \"The Pharmacy Department of the Hospital Clinic in Barcelona produced and safeguarded the computer‐generated randomization list for each recruiting site until unblinding, and carried out the masking, labelling, and packaging of all study interventional drugs. Study number allocation for each participant was concealed in opaque sealed envelopes that were sequentially numbered and opened only after recruitment by study health personnel\".Blinding of participants and personnel (performance bias) All outcomesLow riskQuote: \"Study participants were assigned a unique study number linked to the allocated treatment group. Investigators, laboratory staff, care providers, and study participants were blinded to intervention throughout the study\".\
Placebo tablets were identical to mefloquine tables in shape and colour.Blinding of outcome assessment (detection bias) EfficacyLow riskQuote: \"Investigators, laboratory staff, care providers, and study participants were blinded to intervention throughout the study\".Blinding of outcome assessment (detection bias) SafetyLow riskQuote: \"Investigators, laboratory staff, care providers, and study participants were blinded to intervention throughout the study\".Incomplete outcome data (attrition bias) All outcomesLow riskAll excluded participants, at any stage of the trial, are counted in the flow chart (both ITT and ATP cohorts). Missing outcome data were balanced in numbers across groups.Selective reporting (reporting bias)Low riskNot observed. Protocol availableOther biasLow riskThe study appears to be free of other sources of bias.[@CD011444-bbs2-0006]MethodsTrial design: double‐blind, placebo‐controlled trial. Phase 1 and phase 2\
Follow‐up: in both phases, weekly visits included assessment of weight, temperature, pulse, blood pressure, fundal height, presence of oedema and anaemia, a symptom questionnaire on gastrointestinal and central nervous system side effects, malaria blood smear, electrocardiogram, and haematology and biochemistry every 2 weeks. Treatment of malaria and anaemia and food supply were provided when needed. At phase 2, expanded questionnaires and Romberg test were used. At delivery, measurement of newborn weight, details of labour, cord and maternal blood samples (malaria and anaemia), and placental biopsy were included. At phase 2, autopsy of death was performed in newborns. Follow‐up consisted of different measurements in children until 2 years of age (weight, height, head and arm circumferences) and determination of age when baby could first crawl, sit, walk, and talk. At phase 2, age at first symptomatic malaria, malaria blood smear, haematocrit, and full clinical examination were performed.\
Adverse event monitoring: weekly symptom questionnaire focusing on gastrointestinal, neurological, dermatological, and systemic symptomsParticipantsNumbers of participants randomized: 170 (mefloquine ‐ 60 phase 1, 110 phase 2), 169 (placebo ‐ 59 phase 1, 110 phase 2)\
Inclusion criteria: women of all gravidities and unknown HIV status (not tested) who attended the ANC clinic and were at \> 20 weeks of estimated gestation.\
Exclusion criteria: women not meeting inclusion criteria.Interventions[IPTp with mefloquine]{.ul}\
Phase 1: 500 mg of base loading dose followed by 250 mg weekly for 4 weeks and thereafter 125 mg weekly until deliveryPhase 2: 250 mg of base weekly given for 4 weeks followed by 125 mg weekly until delivery\
[IPTp with placebo]{.ul}\
Identical to mefloquine tablets (weekly dosage)\
The first dose was given at \> 20 weeks of gestation.\
Anaemia was treated with ferrous sulphate and folic acid. Uncomplicated *Plasmodium falciparum* malaria was treated with quinine sulphate, *P vivax* with chloroquine sulphate, and severe malaria with intravenous quinine dihydrochloride.OutcomesMaternal peripheral parasitaemia during pregnancyPlacental malariaMean birth weightLow birth weightPrematurityStillbirthsSpontaneous abortionsCongenital malformationsMaternal mortalityInfant mortalityNotesCountry: Thailand\
Setting: 3 camps for displaced people: phase 1 antenatal clinics, phase 2 hospital\
Dates: 1987 to 1990\
Transmission: seasonal malaria transmission (mesoendemic)\
Resistance: resistances to mefloquine, quinine, chloroquine, and antifolates\
Funding: United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases; Wellcome Trust of Great Britain; Prevention Fundation***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskWomen were randomized to receive mefloquine or placebo. Not well explained how women were randomizedAllocation concealment (selection bias)Unclear riskNot explainedBlinding of participants and personnel (performance bias) All outcomesLow riskDouble‐blind trial\
Quote: \"The investigators were unaware of the randomization\".\
Placebo tablets were identical to mefloquine tablets.Blinding of outcome assessment (detection bias) EfficacyUnclear riskNot explainedBlinding of outcome assessment (detection bias) SafetyUnclear riskNot explainedIncomplete outcome data (attrition bias) All outcomesLow riskAll excluded participants and those who decided to drop out are correctly reported along with reasons. Missing outcome data were balanced in numbers across groups.Selective reporting (reporting bias)Unclear riskResults of cord and maternal blood smears are not shown (published elsewhere?). No protocol is available. Nothing else was observed.Other biasLow riskThe study appears to be free of other sources of bias.[^4]

Characteristics of excluded studies \[ordered by study ID\] {#CD011444-sec2-0020}
===========================================================

StudyReason for exclusion[@CD011444-bbs2-0007]Letter to editor reporting on the results of pregnancy of 24 women exposed to mefloquine in early pregnancy. The report was excluded because it did not meet the inclusion criteria.[@CD011444-bbs2-0008]This publication reports the findings of a re‐analysis of previous published data comparing mefloquine with sulphadoxine‐pyrimethamine for IPTp in Benin using a multiple outcome approach, which allowed the joint assessment of efficacy and tolerability. This analysis was not included in the review because the original study (Briand 2009 BEN) was already included and it did not add additional data.[@CD011444-bbs2-0009]Study comparing mefloquine tolerability as IPTp between HIV‐infected and uninfected women participating in three included trials from Benin (Briand 2009 BEN and Denoeud‐Ndam 2014a and b). This analysis was excluded from the review because it did not provide additional data from already included trials.[@CD011444-bbs2-0010]The study was designed as a dose‐finding pharmacokinetic study in 20 pregnant women in the third trimester of pregnancy who received mefloquine as prophylaxis. The trial did not compare the safety and efficacy of mefloquine with another antimalarial drug and thus, it did not meet inclusion criteria.[@CD011444-bbs2-0011]Publication reporting on a data analysis of reported use of mefloquine during the 1^st^ trimester of pregnancy in European travellers. This analysis was excluded from the review because it did not meet inclusion criteria.[@CD011444-bbs2-0012]This publication presents the analysis of the reports of exposure to mefloquine in pregnancy received by the Roche post‐marketing surveillance system. This analysis was excluded from the review because it did not meet inclusion criteria.[@CD011444-bbs2-0013]This publication reports a case series of 72 US soldiers who inadvertently took mefloquine during pregnancy for prophylaxis. This publication was excluded from the review because it did not meet inclusion criteria.[@CD011444-bbs2-0014]We were not convinced that allocation was unbiased.\
Quote: \"The assignment of regimens was based on the clinic day of enrolment. All women making their first antenatal clinic visit on a given day were assigned to the same regimen; the following clinic day, enrolled women were assigned a different regimen\".\
We noted bias in allocation supported by statistically and clinically significant differences between intervention groups (3 groups under different chloroquine regimens versus 1 group under mefloquine regimen).[@CD011444-bbs2-0015]Study evaluating 1627 reports of mefloquine exposure pregnancy, mainly for chemoprophylaxis received by the Roche Post‐marketing surveillance system between 1986 and 1996.This analysis was excluded from the review because it did not meet inclusion criteria.

Characteristics of ongoing studies \[ordered by study ID\] {#CD011444-sec2-0021}
==========================================================

[@CD011444-bbs2-0016]Trial name or titleA comparative study of mefloquine and SP as prophylaxis against malaria in pregnant HIV‐infected patientsMethodsAllocation: randomized\
Intervention model: parallel assignment\
Masking: single‐blind (outcomes assessor)\
Primary purpose: preventionParticipantsInclusion criteria:\
Pregnant HIV‐infected patientsGestational age ≥ 16 weeksNo history of use of mefloquine or sulphadoxinePyrimethamine 4 weeks before recruitment\
Exclusion criteria:\
Anaemia packed cell volume \< 30%Pre‐existing medical conditions ‐ diabetes mellitus, hypertensionAllergy to sulphadoxine‐pyrimethamine or mefloquineNon‐consenting patientsMultiple gestationKnown psychiatric illnessKnown seizure disorderHistory of severe renal or hepatic diseaseInterventionsMefloquine: 250 mg 3 doses 4 weeks apartSulfadoxine‐pyrimethamine: 500 mg sulphadoxine and 25 mg pyrimethamine, 3 tablets 4 weeks apart for 3 dosesOutcomesNo information availableStarting dateSeptember 2015Contact informationOriyomi O Akinyotu, MBBS; Ibadan: +2348035044590; [oriyomiddoc\@yahoo.com](oriyomiddoc@yahoo.com)NotesWe contacted the study authors, but they could not provide the data to us because the study was part of a thesis not yet defended.

RG, JJA, FtK, and CM designed the study. RG, JJA, and FtK wrote the protocol. RG, CPD, and MP assessed trial eligibility and risk of bias. RG, CPD, and MP extracted data. RG and CPD performed analyses. RG and CPD wrote the first version of the review. All review authors interpreted trial results, contributed to writing of this review, and approved the final version of the review.

Internal sources {#CD011444-sec2-0017}
================

Barcelona Institute of Global Health (ISGlobal), Hospital Clínic‐ Universitat de Barcelona, Spain.Liverpool School of Tropical Medicine, UK.

External sources {#CD011444-sec2-0018}
================

Department for International Development, UK.Grant: 5242

RG, JJA, and CM are authors of two trials of mefloquine to prevent malaria in pregnancy (published in 2014) that are candidates for inclusion in this review. MP has no known conflicts of interest. CPD has no known conflicts of interest. FtK has no known conflicts of interest.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^a^Although one trial has serious risk of bias, the other is of high certainty and exclusion of the smaller trial has little effect on the estimate of effect. ^b^Downgraded by 1 for imprecision: Confidence intervals range from considerable benefit to considerable harm. ^c^Downgraded by 1 for heterogeneity: Substantive qualitative heterogeneity is evident in the meta‐analysis. ^d^Confidence intervals include little or no important difference to a 24% reduction in anaemic women. The estimate of 16% is judged to be clinically important.

[^3]: ^a^Although one trial has serious risk of bias, the other is of high certainty and exclusion of the smaller trial has little effect on the estimate of effect. ^b^Downgraded by 1 for inconsistency: Trials showed substantial heterogeneity. ^c^Downgraded by 1 for imprecision: Confidence intervals range from considerable benefit to considerable harm. ^d^A second RCT, [@CD011444-bbs2-0002], reported 50 events in the mefloquine+cotrimoxazole group and 0 in the control group (cotrimoxazole), with RR 101 (95% CI 6.29 to 1621.68). This trial was open and participants knew to which group they were allocated. Meta‐analysis causes a paradoxically very wide CI. Because of this distortion, we have used the results from [@CD011444-bbs2-0005] in the grade table. ^e^A second RCT, [@CD011444-bbs2-0002], reported 52 events in the mefloquine+cotrimoxazole group and 0 in the control group (cotrimoxazole), with RR 105 (95% CI 6.54 to 1685.03). This trial was open and participants knew to which group they were allocated. Meta‐analysis causes a paradoxically very wide CI with the lower 95% CI. Because of this distortion, we have used the results from [@CD011444-bbs2-0005] in this 'Summary of findings\' table.

[^4]: Abbreviations: AE: adverse event; AECID: Spanish Agency for International Cooperation; ANC: antenatal care; ATP: adenosine triphosphate; CISM: Centro de Investigação em Saúde da Manhiça; IPTp: intermittent preventive treatment for malaria in pregnancy; IPTp‐mefloquine: intermittent preventive mefloquine treatment in pregnancy; IPTp‐sulfadoxine‐pyrimethamine: intermittent preventive sulfadoxine‐pyrimethamine treatment in pregnancy; ITT: intention‐to‐treat; LLITN: long‐lasting insecticide‐treated net; PCR: polymerase chain reaction; PMTCT: prevention of mother‐to‐child transmission; SAE: serious adverse event.
